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Abstract 
 
Characterizing Herpes Simplex Virus type 1 Replication Kinetics, Latency, 
and Reactivation in the Lip Scarification Model of Infection and Disease 
 
Kevin Pollard Egan 
 
 
Herpes simplex virus type 1 (HSV-1) is a common human pathogen 
which infects the majority of adults. The virus establishes a lifelong latent 
infection in sensory neurons and periodically reactivates to cause 
recurrent disease. Most new human infections above the neck occur in the 
lower lip but most animal models of HSV-1 infections do not inoculate 
through the lip. Here we describe  the acute and latent infection events of 
HSV-1 infections in a lip model of HSV-1 infection and disease. Mice 
exhibited clinical lesions and pathology consistent with human HSV-1 
infections. Mice were able to clear the primary infection, establish latency, 
and the resultant latently infected tissue was capable of supporting viral 
reactivation. This HSV-1 infection system was subsequently used to 
perform initial testing of a novel CRISPR/Cas9 gene editing therapeutic. 
Overall, these studies have established the basic events of acute and latent 
infection as well as viral reactivation in mice infected via a lip inoculation. 
x 
 
In addition, these studies have shown the utility of the lip scarification and 
HSV-1 infection and disease model to study molecular pathogenic events 
associated with the establishment, maintenance, and reactivation of latent 
infection and associated disease processes. This model can be used for 
testing a variety of therapeutics for efficacy with respect to reducing viral 
replication and pathology in the lip and to minimize or eliminate acute HSV-
1 infection and/or remove latent viral genomes in order to develop a cure 
for viral reactivation and recurrent HSV-1 infections. 
  
xi 
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1.1. ABSTRACT  
Herpes simplex virus type 1 (HSV-1) is capable of causing a latent 
infection in sensory neurons that lasts for the lifetime of the host. The 
primary infection is resolved following the induction of the innate immune 
response that controls replication of the virus until the adaptive immune 
response can clear the active infection. HSV-1-specific CD8+ T cells 
survey the ganglionic regions containing latently infected neurons and 
participate in preventing reactivation of HSV from latency. The long-term 
residence and migration dynamics of the T cells in the trigeminal ganglia 
appear to distinguish them from the traditional memory T-cell subsets. 
Recently described tissue resident memory (TRM) T cells establish 
residence and survive for long periods in peripheral tissue compartments 
following antigen exposure. This chapter focuses on the immune system 
response to HSV-1 infection. Particular emphasis is placed on the 
evidence pointing to the HSV-1-specific CD8+ T cells in the trigeminal 
ganglia belonging to the TRM class of memory T cells and the role of TRM 
cells in virus infection, pathogenesis, latency, and disease. 
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1.2. Introduction to virus and infection cycle 
Herpes simplex virus (HSV) type 1 (HSV-1) is a ubiquitous human 
pathogen capable of causing an infection that lasts for the lifetime of the 
host as a primary, latent, recurrent, or persistent infection. The HSV-1 
genome is a 152-kbp double-stranded linear DNA genome that encodes 
for upwards of 84 genes (Roizman et al. 2007). The genome is contained 
within the nucleocapsid, which is surrounded by a heterogeneous group of 
proteins collectively designated as the tegument. The tegument and 
nucleocapsid are surrounded by a lipid envelope studded with 
glycoproteins that are used to bind to and enter new susceptible cells. 
HSV-1 is a widespread pathogen that can be found in up to 53% of the 
adult population in the United States, with carriage found to be even 
higher in selected groups of individuals (Xu et al. 2006). A unique feature 
of HSV-1 and other human α-herpesviruses (HSV type 2 [HSV-2] and 
varicella zoster virus; VZV) is the ability to cause a latent infection of 
sensory neurons innervating peripheral tissues. The latent infection is 
maintained for the lifetime of the host and can be periodically interrupted 
by asymptomatic or clinically apparent reactivation events of variable 
duration and severity. The number of recurrent infections in an individual 
with HSV is highly variable, whereas reactivation of VZV is seldom 
observed more than once or twice over the course of a lifetime. The 
natural history of VZV has been dramatically altered by the availability of 
vaccines directed at preventing varicella or chickenpox, the primary 
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disease (Shah et al. 2010), and zoster or shingles, the reactivated form of 
the disease (Oxman et al. 2005). An effective vaccine directed against 
with HSV-1 or HSV-2 has yet to be delivered to the human population to 
prevent either primary or reactivated disease or as a therapeutic modality 
(Chentoufi et al. 2012). 
The HSV-1 infection cycle begins when the virus replicates in 
epithelial cells following transmission to a new uninfected host. HSV-1 
glycoproteins B (gB) and C (gC) are responsible for virion attachment to 
host cells by interacting with heparan sulfate proteoglycans (HSPGs) 
(Shukla and Spear, 2001). Filopodia extending out of cells contain high 
concentrations of HPSGs and viruses have been shown to travel along 
filopodia to cell bodies in a process termed virus surfing (Oh et al., 2010). 
Cells lacking HSPGs can still be infected by virions due to the ability of gB 
to bind to paired immunoglobulin like type 2 receptor alpha (PILRα) (Satoh 
et al., 2008).Glycoprotein B is highly conserved and is essential for virion 
attachment and fusion. Glycoprotein C is considered non-essential as 
viruses lacking gC are still infectious, though they have reduced infection 
efficiency (Shukla and Spear, 2001). 
Following binding to the cell surface, the virus enters through fusion 
at the plasma membrane or endocytic vesicles. Fusion is mediated 
through glycoprotein D (gD) interacting with cellular receptors which 
induces a conformational shift in gD (Carfí et al., 2001). This 
conformational change causes the formation of the multiprotein fusion 
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complex which consists of gD, gB, gH, and gL (Campadelli-Fiume et al., 
n.d.). Glycoprotein D has been shown to be capable of using multiple 
cellular receptors found on numerous cell types for initiation of fusion. 
Herpesvirus entry mediator (HVEM) has been shown to be used by gD for 
entry of HSV-1 into human trabecular meshwork cells (Tiwari et al., 2005). 
Specific isoforms of 3-O sulfated heparan sulfate were shown to be used 
for entry into primary corneal fibroblasts (Shukla et al., 1999). Nectin-1 has 
been shown to be responsible for entry into epithelial cells and importantly 
neuronal cell populations (Shukla et al., 2012; Simpson et al., 2005). 
Additionally PILRα has been shown to enable infection of normally 
resistant cell populations when they are transfected to express PILRα 
(Satoh et al., 2008). HSV-1 has also shown to be capable of entering cells 
through fusion following endocytosis. The mechanism of entry for this 
pathway has not been fully worked out, but it appears that it could be cell 
type and/or receptor specific  (Nicola and Straus, 2004). 
Fusion of the HSV-1 viral envelope with the plasma membrane of 
susceptible cells delivers the tegument proteins and nucleocapsid into the 
cytosol of the target cell. Tegument proteins serve to regulate cell 
processes (Strom and Frenkel, 1987), evade the immune system (Sen et 
al., 2013), and promote transcription of viral genes. Tegument protein 
VP16 (VMW65, or an α-transinducing factor [α-TIF]) associates with host 
cell factor 1 (HCF1) and octamer-binding transcription factor 1 (OCT 1) to 
form a transcription factor complex that strongly promotes the transcription 
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of immediate-early (IE) or α viral genes (Gerster, 1988). The transcription 
of HSV-1 genes proceeds in an organized temporal pattern, with α genes 
being expressed first. The IE gene products serve as activators for the 
transcription of early or β genes, which encode for proteins necessary for 
replication of viral DNA. Following amplification of the viral genome, the 
late or γ genes, which comprise the virion structural components, have 
been shown to be expressed, as previously reviewed (Roizman et al. 
2011). Packaged virions are released and spread to nearby uninfected 
cells, thereby expanding the amount of infectious virus and facilitating the 
spread of the infection to neighboring epithelial cells. Perhaps more 
importantly with respect to the natural history of HSV disease, the virus 
also infects neighboring peripheral sensory neurons during primary 
infection setting the stage for the establishment of latent infection. 
HSV-1 virions bind to and enter axons and travel in a retrograde 
direction towards the neuronal cell body, as previously reviewed (Smith 
2012). After reaching the nucleus of the neuron, the viral genome is 
translocated from the capsid docked at the nuclear membrane into the 
nucleus, where it is thought to circularize in preparation for DNA synthesis. 
The circular form of the HSV genome has also been shown to be the 
predominant form of the genome that is maintained during the course of 
viral latency (Mellerick and Fraser 1987; Su et al. 2002). At the earliest 
stages of nuclear invasion, there are a number of different viral replication 
modes that can be followed which have different consequences for the 
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infected neuron.  In some cases, genomic activation of IE genes by the 
tegument transactivator protein VP16, HCF/OCT, and possibly other 
factors leads to productive infection with synthesis of infectious virions that 
can cause the death of at least some neurons with the potential for 
replication and disease in the periphery after release of the progeny virus 
from neuronal axons in the periphery. However, in some neurons, 
productive infection may be prevented or aborted by the presence of 
neuronal nuclear factors that prevent the activation of the promoters and 
therefore prevent or abort productive replication and send the virus into a 
latent state (Bloom et al. 2010; Cliffe et al. 2009; Knipe and Cliffe 2008). It 
has been proposed that some neurons are more susceptible to productive 
infection whereas some neuronal types might be either reversibly or 
irreversibly susceptible to viral latency based on the differential presence 
of regulatory RNAs or regulatory proteins (Bertke et al. 2012; Bertke et al. 
2011; Yang et al. 2000). The latent infection has been characterized as 
maintenance of the viral genome within the neuron in the absence of 
production of new cell-free infectious virus. Viral gene expression has 
been shown to be limited to the latency-associated transcript (LAT) and 
possibly the low-level expression of other genes (Feldman et al. 2002; 
Kramer and Coen 1995; Ramachandran et al. 2010). The protein and/or 
RNA regulatory factors that guide the virus into latency or that maintain 
the control of the latent state or initiate reactivation are largely unknown 
but are beginning to come to light (Camarena et al. 2010; Kim et al. 2012; 
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Thompson and Sawtell 2011). It may also be possible that the greater 
distance the virus must travel to reach the neuronal nucleus, the lower the 
level of tegument proteins that will be available for promotion of IE gene 
expression (Sears et al. 1991) once the capsid has reached the nucleus of 
the infected neuron. An additional mechanistic theory centers on neuronal 
sequestration of HCF1 in the cytoplasm instead of the nucleus, in which 
case this factor would not be available to interact with VP16 in the nucleus 
to enhance transactivation of early promoters and facilitate productive 
replication (Kristie et al. 1999). In general, a number of studies have 
suggested that it is likely that a combination of viral and host cell factors 
may be responsible for the establishment and maintenance of latent 
infection of neurons. The latent phase has been theorized to be of 
evolutionary benefit to the virus as it maintains a stable reservoir of viral 
genomic information from which periodic reactivations emanate and allows 
for transmission of infectious virus to new hosts over the lifetime of the 
infected host. 
Following selected stimuli, viral gene expression has been shown 
to be enhanced, with infectious virus production first in the ganglia and 
later at peripheral sites. At least a fraction of the newly made capsids in 
the neuronal nucleus are thought to travel anterograde to the axonal 
terminal with release into the periphery (Smith et al., 2001). Reactivation 
of the virus can often be asymptomatic, but replication in peripheral 
epithelial cells can also lead to symptomatic disease. Herpes labialis has 
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been shown to be caused by the formation of vesicular lesions resulting 
from replication in epithelial cells. Rupture of these lesions causes spread 
of the virus to different anatomical regions or transmission to new hosts. 
Usually the disease has been shown to be self-limiting in 
immunocompetent individuals; however, serious disease can occur in 
immunocompromised individuals (Rowley et al., 1990). Replication in 
corneal epithelial cells results in corneal scarring and can lead to herpes 
stromal keratitis, a leading cause of blindness in the United States (Kaye 
and Choudhary 2006). HSV-1 infection of the brain is rare but can lead to 
fatal herpes encephalitis in the absence of early therapeutic intervention 
(Brady and Bernstein 2004).  
1.3. Role of the immune system in HSV-1 infection 
The immune system plays an important role in limiting HSV-1 
replication during primary infection and in maintaining the viral genome in 
a latent state for prolonged periods in the absence of infectious virus 
production and clinical symptoms. Replication in peripheral epithelial cells 
causes production and release of type 1 interferons that activate cells of 
the innate immune system. Activated macrophages secrete interferons 
and cytokines, which recruit and activate additional cells of the innate 
immune response to the site of infection. Type 1 interferons induce an 
antiviral state in uninfected epithelial cells that makes it harder for the virus 
to replicate in these cells as well. Recruited neutrophils induce apoptosis 
in infected cells and phagocytose dying cells. Activated natural killer (NK) 
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cells release interferon-γ and granzymes A and B, which induce apoptosis 
in infected cells. Dendritic cells (DCs) secrete proinflammatory cytokines, 
take up antigen, and present viral peptides to cells of the adaptive immune 
system. The innate immune response limits viral replication in the 
periphery and presents antigen to the naïve lymphocytes to activate the 
adaptive immune response. Previous studies have suggested that the 
principal role of B cells in the immune response to HSV-1 infection is not 
to produce neutralizing antibodies but instead to present antigen and 
secrete cytokines (Deshpande et al. 2000). Activated CD4+ and CD8+ T 
cells play a pivotal role in clearing the primary infection. Additionally, CD8+ 
T cells are important for maintaining the virus in the latent state, as will be 
discussed below (Figure 1.1).  
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Figure 1.1. HSV-1 immune responses. Productive HSV-1 infection 
occurs in epithelial cells in the oral mucosa. Released virons infect 
neighboring cells and innervating sensory neurons. The virus travels 
retrograde to establish latent infection in the trigeminal ganglia. HSV-1 
infection is detected in epithelial cells and induces production of interferon-
β (IFN-β). IFN-β activates innate immune cells, which in turn secrete IFN-
α. Type 1 IFNs induce the antiviral state in an autocrine fashion in the 
producing cell and in surrounding epithelial cells. Interleukin-18 (IL-18) 
released from dendritic cells (DCs) activates natural killer (NK) cells that 
secrete IFN-γ and granzymes A and B (GrzAB). DCs engulf HSV-1 virions 
and travel to the draining lymph node where they activate naïve B and T 
cells. Activated T cells travel back to the site of primary infection and the 
trigeminal ganglia,where they surround infected neurons and prevent 
replication via secretion of IFN-γ and granzymes A and B. 
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Figure 1.1. 
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Detection of HSV-1 infection occurs initially within the infected 
peripheral epithelial cells. Viral pathogen-associated molecular patterns 
(PAMPs) are detected by pattern recognition receptors (PRRs) within 
infected cells and induce intracellular signaling, which results in cytokine 
release and interferon production. Recently, the detection of HSV-1 
PAMPs by cellular PRRs has been reviewed (Melchjorsen 2012; Paludan 
et al. 2011). Extracellular HSV-1 has been detected as a result of gD 
binding to PRRs on the surface of the host cell prior to membrane fusion 
(Ankel et al., 1998; Kim et al., 2012). Intracellular PAMPs such as viral 
nucleic acids are detected either in the cytoplasm or in endosomal 
compartments.  
Viral nucleic acids are the primary PAMPs detected by HSV-
infected cells and readily induce expression of proinflammatory cytokines 
and interferons. The HSV-1 genome has been shown to be composed of 
double-stranded DNA (dsDNA) that contains unmethylated CpG motifs 
(Lundberg et al. 2003). CPG motifs have been detected based on the Toll-
like receptor 9 (TLR-9) being embedded in the membrane of endosomal 
compartments. How HSV-1 DNA has been detected within endosomal 
compartments is not definitively known, but the virus has been shown to 
be capable of infecting cells through endocytosis in addition to membrane 
fusion (Rahn et al. 2011). HSV-1 DNA from infected cells can also be 
endocytosed, where it can be detected by TLR-9 in plasmacytoid DCs 
(pDCs) and B cells (Bosnjak et al. 2012; Pollara et al. 2003). Cytoplasmic 
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DNA sensors detect HSV-1 DNA not found in endosomal compartments. 
DNA-dependent activator of interferon regulatory factors (DAI), interferon-
γ-inducible protein 16 (IFI16), DXH9, and DXH36 detect DNA motifs in the 
cytoplasm. IFI16 has recently been shown to be able to activate and 
maintain normal levels of interferon in the absence of TLR signaling in 
corneal epithelial cells (Conrady et al. 2012). DXH9 and DXH36 detect 
DNA-containing CpG motifs and activate NF-кB and interferon regulatory 
factor 7 (IRF7), respectively. 
Although the HSV-1 virion contains a DNA genome, replication 
intermediates have been detected by PRRs specific for double-stranded 
RNA (dsRNA)  (Weber et al., 2006). Endosomal dsRNA has been 
detected by TLR-3, which has been shown to be expressed in many cell 
types and expression can be induced by type 1 interferons  (Tissari et al., 
2005). The importance of TLR-3 activation in HSV-1 infection has been 
illustrated by children with genetically deficient TLR-3, who have greater 
susceptibility to herpes encephalitis (Guo et al. 2011; Herman et al. 2012; 
Zhang et al. 2007). Recently Lafaille et al. (2012) demonstrated that TLR-
3-deficient CNS cells have reduced intrinsic innate immune activation. 
Taking dermal fibroblasts from TLR-3-deficient patients and generating 
induced pluripotent stem cells of neuronal lineage, they demonstrated that 
TLR-3-negative neurons and oligodendrocytes induce fewer type 1 
interferons in response to HSV-1 infection. Cytosolic viral RNA 
intermediates are detected through retinoic acid inducible gene (RIG)-like 
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receptors (RLRs) that contain DExD/H box helicase domains (Kato et al. 
2008). RIG-I and MDA-5 (melanoma differentiation-associated gene 5) 
recognize short dsRNA (Schlee et al., 2009) and longer dsRNA higher-
order structures (Pichlmair et al., 2009), respectively. RLR signaling 
induces IRF-3 and NF-кB activation, leading to type 1 interferon 
production and proinflammatory cytokine production. 
The interferon-induced antiviral state has been shown to be  
important for limiting the immediate viral replication in susceptible cells of 
the periphery. The difference between the severe response observed in 
BALB/c mice compared with the controlled response in C57BL/6 mice has 
recently been attributed to the enhanced innate response present in the 
C57BL/6 mice (Sheridan et al. 2009). Interferon signaling leads to 
expression of interferon-stimulated genes ribonuclease L (RNAse L), 
protein kinase RNA-activated (PKR), and 2′-5′ oligoadenylate synthetase. 
These antiviral enzymes accumulate in cells in response to interferon 
binding and have been shown to be ready to act upon signs of virus 
infection. PKR phosphorylates EIF-2α, a necessary protein for protein 
translation to proceed. Inhibition of protein translation prevents viral 
replication and causes viral mRNA transcripts to accumulate. Viral mRNA 
transcripts are actively degraded by RNAse L, which has been shown to 
be activated in response to dsRNA and 2′-5′ oligoadenylate synthetase. 
These mediators of translational inhibition are activated in response to 
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PAMPs present within infected cells and thus do not necessarily prevent 
translation in uninfected cells.  
Primary recruited immune cell mediators include monocytes, 
neutrophils, DCs, and NK cells. Attracted neutrophils secrete the antiviral 
molecule tumor necrosis factor-α (TNF-α), which can induce apoptosis in 
infected epithelial cells through a caspase-8-dependent pathway. 
Neutrophils also phagocytose necrotic and apoptotic epithelial cells. 
Monocytes attracted to the area differentiate into tissue macrophages and 
phagocytose released virions and apoptotic cells. Macrophages are 
professional antigen-presenting cells (APCs) that release proinflammatory 
cytokines and present viral peptides to cells of the adaptive immune 
response. Macrophages in peripheral tissue sites where initial infection 
occurs (Cheng et al. 2000; Mott et al. 2007) and in the trigeminal ganglia 
(Kodukula et al. 1999) serve to limit viral replication until the adaptive 
immune system can be activated. Macrophages secrete proinflammatory 
cytokines such as TNF-α, interleukin-6 (IL-6), RANTES (“regulated on 
activation, normal T cell expressed and secreted”), type 1 interferons, and 
nitric oxide (NO). NO production has been shown to be initiated by the 
enzyme inducible nitric oxide synthase (iNOS), which is activated by 
interferon-γ released from γδ-T, NK, CD4+ T, and CD8+ T cells. NO 
released from macrophages has been shown to significantly reduce HSV-
1 levels when treating in vitro macrophage cultures. When iNOS is 
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inhibited in mouse models, virus replication has been shown to increase in 
the trigeminal ganglia (Kodukula et al. 1999). 
Dendritic cells play an important role in the immune response by 
activating NK cells at the site of infection and acting as APCs to activate 
cells of the adaptive immune system. HSV-1 PAMPS activate immature 
DCs which differentiate and mature. Mature DCs can activate other 
immature DCs through the release of type 1 interferons (Pollara et al. 
2004). Mature DCs travel to the draining lymph node, where viral peptides 
are presented to naive B and T cells for activation. Viral peptides can also 
be presented in the context of HSV-1 infection of DCs through a cross-
presentation pathway. HSV-1-infected DCs are unable to mature but are 
still capable of secreting cytokines that activate uninfected DCs; infected 
DCs are also induced to undergo apoptosis via downregulation of C-FLIP 
(cellular FLICE-like inhibitory protein) (Kather et al. 2010). Infected 
apoptotic DCs are taken up by activated DCs which process the antigen 
and present peptides to cells of the adaptive immune system (Bosnjak et 
al. 2012). An additional role of DCs involves the secretion of IL-18, which 
has been shown to be necessary for the activation of NK cells (Kassim et 
al. 2009; Reading et al. 2007). Mice lacking DCs exhibit increased HSV-1 
neurovirulence during the course of infection based primarily on the limited 
activation of NK, CD4+ T, and CD8+ T cells (Kassim et al. 2006). 
Natural killer cells are crucial to controlling HSV-1 virus levels in the 
periphery by directly inducing cell death in infected epithelial cells (Grubor-
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Bauk et al. 2008). Like CD8+ T cells, NK cells contain preformed granules 
of perforin, granzyme A, and granzyme B. HSV-1 infection reduces major 
histocompatibility complex (MHC) class 1 expression in epithelial cells by 
the action of ICP47, a viral immediate-early gene, which blocks loading of 
TAP (transporter associated with antigen presentation) and presentation 
of viral peptides through MHC class 1 (York et al. 1994). The reduction in 
MHC class 1 has been shown to be a signal that NK cells use to target 
virus-infected cells (Ravetch 2000). Recently it has been shown that NK 
cells can also be activated by HSV-1 gD binding to TLR-2 on the surface 
of NK cells (Kim et al. 2012). Mice have been shown to suffer greater 
mortality in response to HSV-1 infection when NK cells are depleted 
(Grubor-Bauk et al. 2008; Williams et al. 1998) or NK survival factor IL-15 
is inhibited in the context of HSV-2 infection (Ashkar and Rosenthal 2003). 
1.4. CD8+ T-cell response 
Antiviral CD8+ T cells exert their effector function through secretion 
of interferon-γ, TNF-α, perforin, and granzymes after engaging antigens in 
the context of MHC class I molecules of the target cells. CD8+ T cells 
induce apoptosis in infected cells by releasing preformed granules or 
through death receptor signaling. The granules contain perforin, 
granzymes, and granulysin, which work together to enter the target cell 
and induce apoptosis. Perforin has been shown to polymerize on the 
target cell membrane forming a pore, allowing entry of granzymes and 
granulysin (Liu et al. 1995; Voskoboinik et al. 2005). However, in the 
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absence of perforin, granzyme B can be internalized by endocytosis into 
the target cell, possibly by interacting with the mannose-6-phosphate 
receptor (Motyka et al. 2000). Although perforin and granzymes are both 
internalized and released into the cytoplasm of the target cell, perforin was 
found to be essential for inducing apoptosis (Froelich et al. 1996). 
Granulysin, a small cationic protein, has been shown to be present in the 
lytic granules of NK cells, NKT cells, helper T cells, and cytotoxic T 
lymphocytes (CTLs) (Latinovic-Golic et al. 2007). This process has been 
shown to cause target cell lysis when it interacts with negatively charged 
cell membrane proteins. Granulysin can also induce apoptosis through the 
release of cytochrome C (Latinovic-Golic et al. 2007).  
Granzymes A and B belong to the serine-protease family and can 
induce apoptosis in caspase -independent and -dependent ways 
(Waterhouse et al. 2006b). Granzyme A acts in a caspase independent 
way to induce apoptosis by cleaving single-stranded DNA and by 
hydrolyzing histone proteins (Fan et al. 2003; Mueller et al. 2003). It can 
also cleave the IL-1β propeptide into the active IL-1β (Irmler et al. 1995; 
Nicola et al. 2005). Granzyme B can induce apoptosis in a caspase-
dependent manner by activating procaspase 3 directly or by increasing the 
permeability of mitochondria and cleaving the Bcl-2 interacting domain 
(Bid) protein (Metkar et al. 2003; Pinkoski et al. 2001).  
CD8+ T cells also respond to viral infections through the production 
and release of interferon-γ. Interferon-γ promotes presentation of viral 
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peptides, inhibits viral replication, arrests the cell cycle, and promotes the 
th1 immune response. Interferon-γ induces expression of 
immunoproteosomal subunits (Belich et al., 1994; Groettrup et al., 1996; 
Kelly et al., 1991) which can enhance processing of viral peptides for 
loading into the MHC class 1 pathway (Sijts and Kloetzel, 2011). 
Interferon-γ also enhances the class 2 antigen presentation pathway, 
increasing expression of MHC 2 molecules in both professional and non-
professional cells (Handunnetthi et al., 2010). Cells exposed to IFN-γ 
inhibit viral replication through expression of antiviral genes like PKR 
which inhibits translation within the cell  (Meurs et al., 1990). Additional 
effects of IFN- γ include increased expression of cyclin dependent kinase 
inhibitors p21 (Xaus et al., 1999) and p27 (Harvat et al., 1997) to arrest 
cell cycle progression. Interferon-γ also skews the immune response by 
promoting differentiation of naïve T cells into Th1 cells (Yoshida et al., 
1994). 
Death receptor signaling is a caspase-8-dependent process of 
inducing apoptosis. CD95 ligand (CD95L) on the surface of CD8+ T cells 
binds with the CD95 receptor to initiate signaling. The CD95 receptor 
contains a death effector domain that is a binding site for procaspase 8. 
Procaspase 8 has been shown to be cleaved upon binding to the death 
effector domain, forming the active caspase 8. Activated caspase 8 can 
then directly cleave procaspase 3, the primary downstream mediator of 
apoptosis. Both granzyme B and activated caspase 8 can cleave Bid to 
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the truncated form (tBid). The activated tBID can induce release of 
cytochrome C from the mitochondria and induce apoptosis through the 
intrinsic pathway (Korsmeyer et al. 2000; Waterhouse et al. 2006a; 
Waterhouse et al. 2006b). 
The mechanisms described above allow virus-specific CTLs to 
efficiently eliminate virus-infected cells from the body by inducing 
apoptosis and thereby limit the virus capacity to produce new virions. This 
mechanism of clearance has been shown to be an effective response to 
viruses in peripheral tissues where apoptotic cells can be replaced by 
mitogenic precursors. However, the neurons that reside in the nervous 
system are nonmitogenic. This presents a problem for the body wherein 
clearance of virus-infected neurons cannot be replaced (Okouchi et al. 
2007). Indeed, previous results have indicated that granule-mediated 
apoptosis by CD8+ T cells may be involved in the control the latent HSV-1 
infection; however, latently infected neurons are rarely induced into 
apoptosis. 
Virus-specific CD8+ T cells infiltrating into the trigeminal ganglia are 
capable of preventing reactivation and maintaining HSV-1 in the latent 
state (Liu et al. 2000). CTLs infiltrate into the trigeminal ganglia, surround 
infected neurons, form immunological synapses, and release preformed 
granules that can be detected within target cells. Yet these molecules do 
not induce apoptosis of latently infected neurons (Knickelbein et al. 2009). 
Granzyme A was shown to act in a noncytolytic capacity to limit the 
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spread of HSV-1 to other neurons, though the mechanism is unknown 
(Pereira et al. 2000). Granzyme B, instead of directly cleaving the normal 
target procaspase 3, instead cleaves the IE protein ICP4 (Knickelbein et 
al. 2009). ICP4 has been shown to be necessary for efficient reactivation 
of the virus, and cleavage by granzyme B has been shown to be a 
noncytolytic mechanism by which CTLs can react to viruses and virus-
infected neurons and thereby control reactivation. 
Additionally, interferon-γ produced by the CTLs plays a pivotal role 
in preventing reactivation. Decman et al. (2005) previously demonstrated 
that interferon-γ is capable of reducing expression of ICP0 promoters, 
possibly by global regulation of transcription factors. Carr et al. (2009) 
showed that transgenic expression of interferon-γ in the trigeminal ganglia 
reduced HSV-1 reactivation in mouse models when exposed to ultraviolet 
light. Another important role of interferon-γ centers on increasing the 
expression of the heavy and light chain of MHC class I molecules in 
addition to chaperones and other proteins that help assemble the peptide–
MHC class I complex (Wallach et al. 1982). Interferon-γ induces 
expression of MHC class 1 in neurons which normally lack MHC class 1 
expression (Wallach et al. 1982). Interestingly, Chentoufi et al. (2011) 
showed that expression of LAT in neuroblastoma cell lines also increased 
expression of MHC class I molecules. To counter increased presentation 
from upregulated MHC class I expression, the HSV-1 IE protein ICP47 
interacts with the TAP proteins and prevents import of antigenic peptides 
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into the endoplasmic reticulum (Oosten et al. 2007). This has been shown 
to inhibit display of HSV-1 antigen on the surface of the neurons. One 
study has suggested that ICP47 activity is required for HSV-1 to infect 
neuronal cells (Burgos et al. 2006). An interesting effect of the mouse 
model of HSV-1 latency has involved the fact that ICP47 from human 
viruses does not efficiently interact with TAP from the mouse, with the 
effect being that HSV peptides are efficiently displayed. This may be the 
reason that mice with latent HSV infection, unlike humans, do not exhibit 
spontaneous reactivations of virus (Feldman et al. 2002). To investigate 
the effect of TAP and MHC Class 1 inhibition by viral proteins on 
reactivation, Orr et al. (2008) generated recombinant HSV-1 virus which 
expressed the murine cytomegalovirus gene m152 (MCMV m152). The 
MCMV m152 gene has been shown to be capable of inhibiting MHC class 
1 export and decreases expression on the cell surface (Tomas et al., 
2010). When mice were infected with the recombinant HSV-1, they 
exhibited increased virus reactivation from latency. However, this model 
does not reflect spontaneous reactivation as it still relies on UV light to 
stimulate reactivation. 
1.5. Latent HSV-1 modulation of apoptosis 
Apoptosis has been shown to be the preferred method that the 
body uses to eliminate viral infections. This pathway leads to programmed 
cell death characterized by DNA fragmentation and membrane blebbing, 
which will be taken up by local immune phagocytes. By inducing cell 
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death, infected cells and the viruses contained within are removed. Most 
cells removed via apoptosis are capable of being replaced by stem cell 
precursors, and thus elimination of the infected host cell is a favorable 
mechanism of limiting viral disease. This process in combination with the 
antiviral state induced by interferon signaling has been shown to be the 
primary method of limiting viral replication in the body and clearing viral 
infections (Benedict et al. 2002). 
Apoptosis can be triggered in multiple ways that work through a set 
of proteases called caspases. These mediators of cell death are 
synthesized as inactive precursors that must in turn be cleaved in order to 
be activated. Proapoptotic stimuli lead to cleavage of procaspase to 
caspase, which then proceed to cleave their own substrates in turn. The 
extrinsic pathway can be activated by a variety of external factors such as 
cytokines, toxins, or ligand binding to death receptors on the cell surface. 
The intrinsic apoptosis pathway is triggered by cell stress factors within, 
such as viral proteins, DNA damage, and oxidative stress, leading to 
dimerization of proapoptotic molecules on the surface of the mitochondria. 
This forms a dimer through which cytochrome C has been shown to be 
released into the cytoplasm. Cytoplasmic cytochrome C associates with 
Apaf1 to activate procaspase 9. Activated caspase 9 complexes with 
Apaf1 and cytochrome C to form the apoptosome, which efficiently 
cleaves and activates procaspases 3 and 7. Both of these pathways 
activate a different set of caspases, which proceed to clean downstream 
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targets. These pathways converge on the activation of procaspase 3, 
which can also be cleaved directly from its precursor from CTL-released 
granzyme B. Activated caspase 3 leads to chromatin condensation, DNA 
fragmentation, and the membrane blebbing characteristic of apoptosis, 
which has been reviewed previously (Elmore 2007; Hengartner 2000). 
Herpesviruses produce numerous antiapoptotic factors aimed at 
delaying or preventing apoptosis to allow for maximal number of infectious 
virions to be produced. Studies performed with specific null mutants have 
revealed that ICP4 (Leopardi and Roizman, 1996), ICP27, Us3 (Aubert et 
al., 2006; Jerome et al., 1999), gD (Sciortino et al., 2008) , gJ (Jerome et 
al., 2001), and LAT all have antiapoptotic functions in vitro, though the 
mechanism is not fully understood for all of them. Recent data has 
suggested that cathepsins are involved in ICP4- and Us3-mediated 
inhibition of apoptosis (Peri et al., 2011).  Antiapoptotic gene transcription 
in productively infected epithelial cells allows the virus to evade apoptosis, 
and the cell dies from damage induced by viral replication. The LAT intron 
is the predominant transcript that can be recovered from latently infected 
neurons and conveys resistance to apoptosis. Although not absolutely 
required for establishment of latency, it does play an important role in 
maintenance, and reactivation of latency, in addition to the antiapoptotic 
effects associated with these RNAs (Bloom 2004).  
The antiapoptotic effects derived from LAT in latently infected 
neurons have not been fully elucidated. The unstable 8.3-kb primary LAT 
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has been shown to be processed to form a stable 2.0- or 1.5-kb intron  
(Wagner et al., 1988). HSV-1 LAT null mutants confer decreased 
protection from cold shock–induced apoptosis (Carpenter et al. 2007). 
Using specific HSV-1 deletion mutants, Branco and Fraser (2005) 
localized the antiapoptotic function in the first 1.5-kb region following the 
LAT promoter. Granzyme B–mediated apoptosis via direct cleavage of 
procaspase 3 was inhibited by LAT expression (Jiang et al. 2011). LAT 
has also been shown to inhibit caspase-8-dependent apoptosis induced 
through death receptor binding (Jin et al. 2010). LAT upregulated 
expression of the prosurvival protein AKT, which prevented the intrinsic 
apoptotic pathways initiated within cells (Figure1.2.) (Li et al. 2010; 
Manning and Cantley 2007). 
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Figure 1.2. Expression of latency-associated transcript (LAT) inhibits extrinsic 
and intrinsic apoptotic pathways. The extrinsic pathway involves proapoptotic 
triggers provided by activated immune cells. Virus-specific CD8+ T cells induce 
apoptosis by death receptor binding. CD95 ligand binding causes the formation 
of the death-induced silencing complex, which binds and activates procaspase 8. 
Activated caspase 8 activates procaspase 3, which leads to apoptosis. LAT 
expression is capable of inhibiting the caspase-8-dependent pathway, but the 
mechanism is unknown. CD8+ T cells releasing preformed granules induce 
apoptosis by direct cleavage of procaspase 3. Perforin forms a pore on the 
surface of target cells and allows entry of granzyme B (GrzB). Granzyme B 
cleaves and activates procaspase 3, leading to apoptosis. LAT inhibits this 
pathway by inhibiting granzyme B from activating procaspase 3. The intrinsic 
apoptotic pathway is initiated by dimerization of proapoptotic molecules on the 
surface of the mitochondria. Released cytochrome C associates with APAF1 and 
activates procaspase 9. Activated caspase 9 activates procaspase 3. Expression 
of LAT activates AKT, which prevents the accumulation of proapoptotic 
molecules. 
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Figure 1.2. 
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The LAT sequence does contain eight putative open reading 
frames (ORF) that could encode for antiapoptotic proteins; however, HSV-
1 LAT-associated proteins have not been isolated (Drolet et al., 1998). 
There is circumstantial evidence for LAT-associated proteins within latent 
infections. Henderson et al. (2009) generated synthetic peptides from the 
LAT ORF sequences and injected these into rabbits to generate antisera 
against the peptides. Antisera from two of the peptide sequences bound to 
protein with neuronal cell cultures. Additionally, immunohistochemistry 
staining of latently infected trigeminal neurons was also positive utilizing 
these antisera. However, the role of LAT-associated proteins is still 
controversial. The structure, abundance, and activity of these proteins 
have not been thoroughly investigated; it has been proposed that it may 
be possible that they play a role in inhibiting apoptosis of infected neurons 
but there will need to be further studies to establish this functional 
connectivity. 
An additional mechanism of antiapoptosis activity could lie in the 
encoding of viral microRNA within the LAT (Jurak et al. 2012). Because of 
the compact nature of viral genomes in which viruses must package 
everything they need for productive infection, the encoding of microRNAs 
in nontranscribed regions and untranslated regions of exons can provide 
important regulatory elements at the transcriptional level (Boss and Renne 
2010; Gottwein and Cullen 2008; Skalsky and Cullen 2010). Using deep 
sequencing analysis of postmortem latently infected trigeminal ganglia; 
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Umbach et al. (2009) identified seven miRNAs encoded by the HSV-1 
LAT, all of them contained within the unstable 6.3-kb exon. These miRNAs 
have been recovered from postmortem human trigeminal tissues, 
demonstrating their presence in human HSV-1 infections. The targets for 
all of the miRNAs have not yet been identified, but miR-H2 has been 
demonstrated to target ICP0 and miR-H6 targets ICP4 (Umbach et al., 
2008). Recently it has been shown that mutation of these miRNAs 
decreases replication of HSV-1 within neurons but has no effect on 
replication within fibroblasts (Flores et al., 2013).  ICP0 and ICP4 are 
potent activators of the β genes and are necessary for reactivation. 
Additionally, ICP0 expression can induce apoptosis through damage of 
cellular structures (Sanfilippo and Blaho 2006). The LAT-encoded miRNAs 
are contained outside of the vital first 1.5-kb region, which has been 
shown to be necessary for protection from apoptosis, so it is unlikely these 
are the main mechanism involved in the inhibition of apoptosis. However, 
by regulating viral gene transcription, miRNAs can help maintain the virus 
in a latent state within neurons and prevent expression of proapoptotic 
genes. Similar to the miRNAs, LAT encodes two small RNAs (sRNAs). 
LAT sRNA2 has been shown to hybridize to the ICP4 transcript and 
reduce its expression. Additionally, sRNA1 and sRNA2 act synergistically 
to inhibit apoptosis induced by cold shock (Shen et al. 2009). The 
mechanisms by which LAT prevents apoptosis are not yet known, but LAT 
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appears to promote the latent state through viral gene regulation by 
miRNAs and sRNAs encoded within LAT (Figure 1.3.). 
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Figure 1.3. Small noncoding RNAs in the latency-associated 
transcript (LAT) gene promote latency. Low-level expression of lytic 
genes ICP0 and ICP4 could lead to spontaneous reaction. The LAT gene 
encodes two different small noncoding RNA species that prevent low-level 
ICP0 and ICP4 expression. The LAT gene encodes seven microRNAs 
(miRNAs) that have been confirmed in vivo. Of these, two miRNAs, miR-
H2 and miR-H6, have confirmed inhibitory effects on ICP0 and ICP4 
protein expression; miR-H2 acts on ICP0 and miR-H6 acts on ICP4. By 
preventing translation of lytic genes required for reactivation, small 
noncoding RNAs derived from LAT promote the maintenance of latency. 
Granzyme B (GrzB) and interferon-γ (IFN- γ) released from CD8+ T 
lymphocytes also contributes to the maintenance of latency. GrzB cleaves 
the ICP4 protein and IFN-γ inhibits expression of ICP0.  
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Figure 1.3. 
 
 
  
34 
 
In contrast to latently infected neurons, productively infected cells in 
the periphery undergo cell death. Peripheral epithelial cells are susceptible 
to lytic infection leading to necrosis during productive HSV-1 replication. 
Other cell types including monocytes and DCs can be induced to initiate 
apoptosis from both intrinsic proapoptotic stimuli from the virus and from 
exogenous signals from immune cells (Mastino et al. 1997; Peri et al. 
2011). In order to definitively identify which cells are susceptible to 
apoptosis, Esaki et al. (2010) exposed mice to HSV-1 and HSV-2 using 
three different inoculation techniques and collected various tissues for 
HSV-1 antigen staining and apoptotic markers. They found that cells such 
as those of the corneal epithelium and neurons in the CNS are sensitive to 
induction of apoptosis when infected by HSV-1. They also found that cells 
within the trigeminal ganglia, although susceptible to HSV-1 infection, 
were not apoptotic. These results fit well with previous experiments that 
have shown that corneal epithelia cells from both animal models and 
humans undergo apoptosis when infected with HSV-1 (Stuart et al. 2004). 
However, this has been challenged by Miles et al. (2007), who 
demonstrated that although apoptosis is induced during productive 
infection of corneal epithelial cells, HSV-1 has been shown to be capable 
of inhibiting the later stages of apoptosis.  
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1.6. Maintenance of latency requires careful balance of factors 
During neuronal latency, a careful balance has been shown to be 
established to maintain the virus in the latent state. The contributors to this 
balance include the neuronal environment, LAT, and the CD8+ T cells 
surrounding the neurons. During latency, the LAT intron has been shown 
to be the predominant transcript that is made from the viral genome 
(Wagner et al., 1988). There is evidence, however, of low-level lytic gene 
expression despite the presence of repressive chromatin modifications 
(Ramachandran et al., 2010). It has been suggested that in neuronal 
cultures, low-level gene expression is required for the production of VP16, 
a γ gene. Once VP16 has been made, the VP16 transcription complex can 
form and bind to the lytic gene promoters, leading to production of 
infectious virions (Kim et al. 2012). It is this low-level gene expression that 
was detected by surrounding CD8+ T cells that release interferon-γ and 
granzyme B, mediators capable of inhibiting lytic gene expression. 
Disruption of CD8+ T-cell inhibition of viral lytic gene expression could lead 
to reactivation from initial ganglionic neuron steady state low-level gene 
expression. Some of the specific stimuli associated with reactivation 
include menstruation in women and psychological and physiological 
stress. Treatment with medroxyprogesterone acetate, a synthetic 
analogue of the female sex hormone progesterone, released during 
ovulation, has been shown to be capable of reducing CD8+ T-cell levels in 
the trigeminal ganglia of latently infected mice (Himmelein et al. 2011). 
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Psychological and physiological stress have also resulted in a reduction of 
CD8+ T cells in the trigeminal ganglia and reduced capacity to secrete 
interferon-γ (Freeman et al. 2008). The stress response is mediated 
through release of the glucocorticoid cortisol, which has been shown to 
reduce interferon-γ expression in T cells (Curtin et al. 2009).  
 The mechanism by which CD8+ T cells inhibit lytic gene expression 
has been shown to be through the release of interferon-γ and granzymes 
A and B. Release of granzyme B has been shown to be a primary method 
through which CD8+ T cells induce apoptosis in virus-infected cells. 
However, neurons harboring latent HSV-1 are protected from granzyme 
B–induced apoptosis (Knickelbein et al., 2009). The exact mechanisms of 
this protection have not been thoroughly explored, but it appears that LAT 
is critical for inhibiting apoptosis in infected neurons (Jiang et al., 2011). 
The inhibition of apoptosis in latently infected neurons reflects the other 
side of the careful balance that allows the latent infection to be 
maintained. Disruption of this balance is another mechanism through 
which external stimuli can potentially induce reactivation. If neurons that 
harbor the latent viral genome are induced to undergo apoptosis, the virus 
reactivates and releases infectious virions (Figure 1.4). The pathway 
through which apoptotic signals initiate reactivation is unknown. This is 
potentially a mechanism by which physical damage to neurons induces 
reactivation. Additionally, apoptotic signals can be a mechanism by which 
ultraviolet (UV) light could induce reactivation from latency. The axons of 
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innervating neurons extend into the periphery and are in proximity to the 
surface of the skin, and could be susceptible to UV light exposure. UV 
light can induce apoptosis in cells through either direct damage of DNA or 
by production of reactive oxygen species (ROS) (Kulms et al., 2002). 
Mitochondria in neurons are uniformly distributed throughout the neuron, 
including the axon (Hollenback 1996). UV light exposure can induce 
production of ROS in mitochondria residing near the axonal terminal, 
which could lead to apoptotic signaling. ROS has been associated with 
reducing expression and levels of Bcl-2 and inhibiting mammalian target of 
rapamycin (Alexander et al. 2010), responses that have been shown to 
induce reactivation (Kobayashi et al. 2012). 
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Figure 1.4. Pathways of stimuli induced reactivation.  Low-level 
temporal expression of lytic genes can lead to production of the 
transcription factor complex and efficient temporal expression of lytic 
genes. This low-level expression has been shown to be inhibited by 
factors released from surrounding CD8+ T cells. Interferon-γ (IFN-γ) 
inhibits ICP0 expression and granzyme B (GrzB) has been shown to 
cleave the ICP4 protein required for efficient expression of lytic genes. 
Stimuli such as hormone imbalance and stress inhibit CD8+ T-cell activity, 
which allows low-level lytic gene expression to continue. Lytic gene 
expression leads to assembly of viral components, release, and 
reactivation (right). Alternatively, stimuli such as UV light and physical 
trauma initiate gene transcription through apoptotic signals. Apoptotic 
signaling leads to uncoordinated expression of lytic genes and production 
of new infectious viruses and reactivation (left). 
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Figure 1.4. 
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Studies by Du et al. (2012) have previously demonstrated an 
interesting feature of the reactivation process when neurons are treated 
with chemical agents that reduce the levels of Bcl-2 and Bcl-xl. 
Interestingly, during this process the expression of the viral genome did 
not proceed according to the ordinary temporal pattern observed in 
primary infection. In contrast to sequential expression of the α, β, and γ 
genes, all gene classes were expressed at the same time upon induction 
of apoptosis. This is a mechanism by which the virus can rapidly produce 
new virions in response to signals that indicate that the cell in which it is 
residing is no longer viable. Rapid virus assembly and escape allows the 
virus to infect peripheral epithelial and neuronal cells to remain in the host 
while being transmitted to other individuals during recurrent disease. 
1.7. Tissue resident memory T cells and HSV-1 infection 
It is possible that the CD8+ T cells surrounding latently infected 
ganglia belong to a novel subset of memory T cells recently described 
called tissue resident memory T cells (TRM). Following antigenic exposure, 
two distinct populations of memory T cells are normally found. Central 
memory T (TCM) cells are retained in secondary lymphoid organs and have 
the capacity to rapidly proliferate upon reexposure to antigen. These are 
characterized by specific cell surface markers CD44+ CCR7+ CD62L+. In 
contrast to central memory T cells, effector memory T (TEM) cells are 
CD44+ CCR7- CD62L- (Harty and Badovinac 2008). The TEM cells circulate 
through the blood and numerous tissues, sampling the environment for 
41 
 
their specific antigen. These cells are already differentiated and are 
capable of immediate effector functions and can begin clearing infections 
without the need to proliferate and differentiate. Memory T-cell responses 
provide fast responses to reinfection, as opposed to how they respond to 
novel antigens, but they rely on the specific antigen to be delivered to 
secondary lymphoid organs (for TCM cells) or for the antigen-specific TEM 
cell to be present at the site of reinfection at the same time. A population 
of memory T cells that reside long-term at the site of initial infection would 
be capable of immediate response to antigenic exposure in the site where 
exposure is likely to occur.  
Recent evidence supports the notion of a distinct population of 
memory T cells that are retained in the tissue of initial exposure. TRM cells 
have been found in numerous tissues in the body, including brain 
parenchyma (Hawke et al. 1998), skin (Gebhardt et al. 2009), genital 
mucosa (Tang and Rosenthal 2010), gut ileum (Masopust et al. 2010), 
salivary glands (Casey et al. 2012), and the dorsal root ganglia (DRG) 
(Gebhardt et al. 2009). Although surface marker characterization has not 
been done with TRM from all these locations, some distinctive phenotypic 
markers have been identified. TRM cells are CD44+ CCR7- CD62L- CD69+ 
CD103+ (Wakim et al. 2012). CD103 has not been found in all tissue 
sources of TRM cells, but it does appear in the majority of TRM cells 
isolated. CD103 is the α chain of the α4β7 integrin receptor for E-cadherin 
normally expressed in epithelial cells (Cepek et al., 1994). An important 
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characteristic of TRM cells is that they do not migrate through the periphery 
or enter into the secondary lymphoid organs; expression of CD103 likely 
allows TRM cells to be retained in tissue compartments. TRM cells have 
been shown to be capable of persisting for extended periods in these 
peripheral tissue compartments without replenishment from the circulating 
pool of CD8+ T cells owing to low homeostatic turnover (Gebhardt et al. 
2009; Masopust et al. 2006). An interesting distinction of TRM cells is their 
apparent ability to survive without IL-15 signaling, even in the absence of 
antigenic exposure (Wakim et al. 2010). The combination of CD103 
expression and long-term residence in tissues where antigen was initially 
encountered distinguishes TRM cells from the established memory T cells.  
With the recent characterization of TRM cells, it is important to 
analyze what other T-cell populations might belong to this novel subclass. 
In latent HSV-1 infection, CD8+ T cells surrounding infected neurons in the 
trigeminal ganglia persist for the lifetime of the organism and are vital in 
maintaining the virus in a latent state (Hoshino et al. 2007; Liu et al. 2000). 
This is accomplished through expression of effector molecules, and 
therefore HSV-1-specific CD8+ T cells have an activated phenotype akin 
to effector memory cells. Activated CD8+ T cells have the markers CD69, 
CD44, CD25, and CD49d expressed on their surface. They downregulate 
homing receptors CD62L and CCR7 (Barrat et al. 1995; Lynch et al. 1989) 
and the markers of naïve CD8+ T cells CD27 and CD28 (Verjans et al. 
2007). Additionally, the CD8+ T cells in the trigeminal ganglia express 
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granzymes A and B and interferon-γ. Like TRM cells, IL-15 is not required 
to maintain the population within the trigeminal ganglia (Sheridan et al. 
2006). The α4β7 integrin CD103 is a marker used to consistently identify 
TRM cells, but no experiments have addressed whether CD103 is present 
on the surface of trigeminal ganglia resident CD8+ T cells. 
Additionally, the migration pattern of CD8+ T cells differs 
extensively from patterns observed with TEM cells. Principally, CD8+ T cells 
never leave the trigeminal ganglia once they have infiltrated and 
surrounded latently infected neurons (Khanna et al. 2003). Whereas TEM 
cells migrate through numerous tissues and can participate in peripheral 
immune responses to antigen reexposure, CD8+ T cells reside in the 
trigeminal ganglia for the lifetime of the host. Himmelein et al. (2011) 
provided evidence of the peculiar homing pattern of the HSV-1-specific 
CD8+ T cells retained in the trigeminal. Following treatment with 
corticosteroids and challenged with restraining stress, stimuli proven to 
reduce CD8+ T-cell levels in the trigeminal ganglia (Elftman et al. 2010; 
Freeman et al. 2008), the population of CD8+ T cells in the trigeminal 
ganglia is quickly reestablished (within 4 days). Importantly, the trigeminal 
population is not supplemented with CD8+ T cells from the circulation, nor 
is it due to proliferation of residual CD8+ T cells in the trigeminal ganglia 
immediately after the treatment. These results imply that the CD8+ T cells 
that left the trigeminal ganglia are capable of homing back to their original 
location. CD8+ T cells in the periphery are incapable of infiltrating the 
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trigeminal ganglia, which prevents supplementation or replacement of the 
population from the circulating pool of CD8+ T cells. The same population 
is not maintained based on the proliferation of resident CD8+ T cells; 
instead, these cells have very low homeostatic turnover.  
Currently available information on trigeminal resident CD8+ T-cell 
surface markers indicates they could fall into either the TEM class or the 
recently discovered TRM class (Table 1.1.). The migration dynamics are 
the primary evidence that the trigeminal ganglia resident CD8+ T cells 
could be TRM cells instead of TEM cells. These T cells are retained in the 
same tissue compartment for the lifetime of the host and home back to the 
same location if dislodged. These cells survive in the tissue compartment 
without being replenished from circulating pools of CD8+ T cells, have low 
homeostatic turnover, and do not require IL-15 for survival. Further 
characterization of the cell surface phenotype of this cell population is 
needed to definitively classify them as being either TRM or TEM cells. 
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Table 1.1. 
Table 1. Phenotypic markers of memory CD8+ T cells 
Memory T-cell subtypes 
 
TCM TEM TRM 
Trigeminal 
ganglia resident 
CD8+ T 
CD44 + + + + 
CD69 - - + + 
CD103 - - +  
Tissue 
retention 
+ - + + 
Effector 
function 
- + + + 
 
TCM, central memory T cells; TEM, effector memory T cells; TRM, tissue resident 
memory T cells. 
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1.8. TRM cells and immunity to viruses 
Gebhardt et al. (2009) studied the response of TRM cells to 
reinfection extensively in the context of HSV-1 skin infection. Following 
flank infection with HSV-1, they found an accumulation of adoptively 
transferred HSV-1-specific CD8+ T cells ipsilateral to the infection site but 
not on the control infection site. These cells were located in the epithelial 
layer of skin; had a surface marker phenotype CD69+ VLA1+ CD103+ 
CD62L- CD122-; did not migrate; and had a slow homeostatic turnover. 
Importantly, when challenged with virus following a previous exposure and 
clearance of virus, the skin flanks with residing TRM cells had much better 
protection than the control flank. This enhanced protection was shown to 
be T-cell dependent, with contributions from both CD4+ T and CD8+ T 
cells. Eliminating CD4+ T cells had a significant effect on clearance, but 
when provided with excess CD8+ T cells, they were capable of clearance 
without the help of CD4+ T cells. 
It is important to note that the results described above involved 
reexposure to exogenous virus and cannot be directly related to skin TRM 
cells responding to reactivation of virus. Mouse models of latent HSV-1 
infection have very rare episodes of spontaneous reactivation (Gebhardt 
and Halford 2005), and thus chemical agents or stressful stimuli, which 
often decrease trigeminal ganglia resident CD8+ T cells, are required for 
reactivation. It is unknown what effect these agents might have on TRM 
cells in the skin and whether they have any effect on virus clearance. 
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Humans do experience spontaneous reactivation or reactivation as a 
result of certain exogenous agents. Reactivation of latent virus can result 
in asymptomatic shedding of virus or may cause formation of recrudescent 
lesions in the same peripheral location where the primary infection 
occurred. Recurrent disease provides circumstantial evidence that if TRM 
cells exist in humans, they either do not prevent reinfection where they 
reside or the agent responsible for reactivation also has an effect on 
peripheral TRM cells.  
Rates of reactivation are inversely correlated with the number of 
CD8+ T cells infiltrating the trigeminal ganglia and have been directly 
correlated with the number of latently infected neurons (Hoshino et al. 
2007). Initial hopes that HSV-1-specific CD8+ T cells could be expanded in 
vitro and then returned to the host as a method to reduce reactivation 
rates have failed because adopted CD8+ T cells cannot access the 
trigeminal compartment where latently infected neurons reside (Himmelein 
et al. 2011). It is possible that critical comparisons of circulating and 
resident ganglionic CD8+ T cells will reveal new information that will make 
it possible to adoptively transfer T cells into the trigeminal compartment in 
order to reduce reactivation and recurrent disease. This method would not 
be capable of eliminating the latent infection, but a robust immune 
presence is capable of limiting virus reactivation from latency. 
Despite decades of research on HSV-1, there is still no effective 
vaccine that can prevent virus infection or control reactivation (Dervillez et 
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al., 2012). Following primary infection in the periphery, released virions 
encounter and infect innervating sensory neurons. The virus attaches to 
the axonal termini and releases the capsid and tegument proteins. The 
capsid and possibly one or more of the tegument proteins migrate 
retrograde towards the neuronal soma where the DNA is uncoated, 
injected into the nucleus.  Viral latency is established very early during the 
course of the primary infection in at least a subset of infected neurons. 
During reactivation, capsids are assembled in the nucleus and then 
transported across the nuclear membrane as enveloped particles. Once in 
the neuronal cytoplasm they are thought to travel, as enveloped or 
possibly nonenveloped particles, anterograde towards the axonal terminal 
region with infectious virions released into the periphery to infect other 
cells as cell-free virus or possibly by mechanisms involving cell-to-cell 
transfer of neuronal membrane-associated virus particles (Smith, 2012). 
This implies that during the migration of virus from the latent reservoir to 
target cells, few locations exist where neutralizing antibodies can act upon 
the virus before it is exposed to target cells. There is a robust immune 
response leading to expanded CD8+ T-cell populations surrounding 
infected cells in the trigeminal, but these cells are incapable of eliminating 
the virus, only of limiting viral reactivation. This means that the primary 
location where a vaccine must be effective is the site of primary infection.  
Mackay et al. (2012) revealed that expanded HSV-specific TRM cells 
in the periphery are capable of limiting disease from reexposure to HSV-1. 
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These experiments suggest an exciting new direction for developing a 
vaccine to prevent new infections or limiting the severity of recurrent 
disease. Shin and Iwasaki (2012) adapted this concept and hypothesized 
that a “prime and pull” technique can generate large numbers of virus-
specific CD8+ T cells in the periphery, where they can stop or limit damage 
from infection. The “prime” is composed of a subcutaneous injection of 
thymidine kinase (TK-) HSV-2 virus, capable of activating and proliferating 
adoptively transferred CD8+ T cells. The “pull” is accomplished by topical 
treatment of CXCL9 and CXCL10 chemokines applied to the vaginal 
cavity. The chemokine treatment attracted many more CD8+ T cells to the 
vagina compared with immunization without chemokine treatment. 
Treatment provided after the central pool of CD8+ T cells had been 
activated successfully recruited and maintained T cells in the genital tract 
for up to 12 weeks after treatment. When challenged with a lethal dose of 
wild-type HSV-2, mice receiving the immunization and chemokine 
treatment suffered less weight loss, did not develop clinical symptoms, 
and had a 100% survival rate. Importantly, viral titers found in the DRG 
following WT infection were significantly decreased compared with 
immunization alone. Because reactivation rates are directly correlated with 
latent viral load, a therapeutic intervention that lowers the initial viral 
infection of the DRG would be beneficial. This novel vaccine treatment 
appears to have successfully lowered the viral burden in the DRG, 
50 
 
decreased the number of latent viral genomes, and would likely 
significantly decrease reactivation and recurrent disease in humans. 
1.9. Conclusions 
HSV-1 represents a persistent human pathogen that resides in 
infected hosts for their lifetime. Clearance of the primary infection follows 
establishment of the latent infection within the ganglionic clusters of 
innervating sensory neurons. Reactivation of the virus is controlled at least 
in part by CD8+ T cells that surround latently infected neurons. An 
important feature of these cells is their long-term residence in the neuronal 
tissue compartment. HSV-1-specific CD8+ T cells can remain in the 
trigeminal ganglia for the lifetime of the host, do not rely on replenishment 
from circulating CD8+ T cells, and have the capability to home back to the 
trigeminal ganglia if displaced. These behaviors distinguish the resident 
ganglionic CD8+ T cells from the traditional CD8+ T-cell memory subsets. 
Recently a new class of CD8+ memory T cells that reside in 
peripheral tissue compartments has been characterized. The phenotypic 
characteristics of the TRM cell are similar to those of the trigeminal ganglia 
resident CD8+ T cells that arise in response to HSV-1 infections. Both cell 
types exist in peripheral tissue compartments for long periods, have low 
homeostatic turnover, are not replenished from the circulating CD8+ T cell 
pool, and express the effector molecules interferon-γ and granzyme B. 
The CD103 integrin receptor is a surface marker used to identify TRM cells 
in peripheral tissues, but its expression has not been evaluated in 
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trigeminal ganglia resident CD8+ T cells. Identification of HSV-1-specific 
CD8+ T cells as TRM cells can lead to exploration of new approaches 
towards reducing disease in humans. Discovery of the factors associated 
with homing of the trigeminal resident CD8+ T cells back to the peripheral 
nervous system compartment may lead to new ways of bolstering the 
CD8+ T-cell levels in the trigeminal ganglia to lower reactivation rates. 
New vaccine approaches designed to attract and retain TRM cells in 
peripheral tissue locations in response to immunization could lower viral 
burden on peripheral nervous system following exposure to virus.  
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2.1. ABSTRACT 
The lip scarification model of herpes simplex virus type 1 (HSV-1) infection 
can be used to study acute infection in the epithelial anatomical surfaces of the 
mouse lip and the establishment of viral latency.  Adult mice were infected with 
HSV-1 McKrae and during the acute phase of infection, epithelial and ganglionic 
tissues were harvested and analyzed. Clinical presentation of classical open 
sores on the epithelial surface of the lips of infected mice was observed. We 
further defined the histopathology and immune infiltration of the lower lip during 
the formation and resolution of the clinical lesions. Finally, the kinetics of virus 
replication and transport of viral genomes to the trigeminal ganglia were 
established. With the virological and immunological events of acute infection 
defined, the HSV-1 lip scarification model can now be used to continue studies 
focused on primary viral infection, invasion of the peripheral nervous system, 
establishment of virus latency, and the viral and host factors involved in 
modulating the latent state and the reactivation process. 
 
  
72 
 
2.2. INTRODUCTION 
Herpes simplex virus type 1 (HSV-1) is a pervasive human pathogen 
which is predicted to infect up to 90% of adults worldwide (Xu et al., 2006). The 
majority of new human infections occur in the oral mucosa directly adjacent 
epithelial surfaces during childhood. Following replication in the periphery, the 
virus establishes a latent infection in the trigeminal ganglia (TG) which persists 
for the lifetime of the host. Periodic reactivations cause recrudescent lesions in 
orofacial tissue termed herpes labialis or cold sores. Infected persons are 
capable of shedding the virus asymptomatically (Schulte et al., 2014), though 
shedding of virus increases in those suffering symptomatic reactivations (Mark et 
al., 2008). Immunocompromised individuals who cannot control replication of the 
virus during acute and latent stages are at greater risk for more severe systemic 
disease with potential invasion of the central nervous system (CNS) and the 
development of encephalitis (Tan et al., 2012).  
Initial infection of the lip comes from a compromise in the epithelial barrier, 
providing the virus with access to the underlying keratinocytes. Infection in the 
epithelia causes localized pathology within the lip and activation of the immune 
response. Infected epithelial cells display characteristic viral inclusions bodies 
including multinucleated cell bodies, keratinocytes with steel grey nuclei,  
orthokeratosis, and chromatin margination (Leinweber et al., 2006). Infection of 
the epithelial area surrounding hair follicles leads to a condition called herpes 
folliculitis (Böer et al., 2006). The histopathology of herpes folliculitis can differ 
from other HSV-1 infections by a lack of multinucleated cell bodies and steel grey 
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nuclei, however, dense immune infiltrates surrounding hair follicles and necrotic 
keratinocytes can be observed. After establishing infection in the epithelia, the 
virus gains access to innervating sensory neurons from the trigeminal ganglia. 
Retrograde transport from the epithelia to the trigeminal ganglia is followed by 
establishment of viral latency for the lifetime of the host.  After any of a number of 
physiological stimuli, reactivation of viral gene expression and replication occurs, 
the virus travels in an anterograde direction down the same infected sensory 
neurons, with viral infectivity transferred to neighboring cells in the periphery to 
establish a new infection in the epithelia in close anatomical proximity to the 
primary infection and termed recurrent infection/disease.  
There is a dense accumulation of sensory nerve endings in the skin of the 
lower lip. These nerve endings convey information on mechanical, thermal, 
chemical, touch, and pain stimuli through A-beta, A-delta, C type fibers 
(Yosipovitch and Papoiu, 2012). The sensory nerves together form the mental 
nerve which is responsible for sensory perception in the lower lip and chin. The 
mental nerve inserts into the mental foramen and combines with other sensory 
branches to form the inferior alveolar nerve. The inferior alveolar nerve and 
lingual nerve together form the mandibular branch of the trigeminal ganglia 
(Wilson-Pauwels, 2001). These neuronal cells are the likely major targets of 
HSV-1 infection in the lip epithelium during the course of primary infection and 
subsequent reactivation events. During reactivation, trigeminal neuralgia has 
been reported to occur in the peripheral regions where reactivation is going to 
occur. The neuralgia is likely due to irritation of the sensory neurons during HSV-
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1 reactivation and can be an early symptomatic sign of recurrent disease 
(Gonzales, 1992).   
The immune system plays a crucial role in restricting viral replication to the 
periphery, resolving the primary infection, and maintaining the virus in latency as 
previously reviewed (Egan et al., 2013). An interesting facet of HSV-1 biology is 
that the double-stranded RNA (dsRNA) sensory Toll Like Receptor-3 (TLR-3) 
appears to be important with respect to preventing the virus from gaining access 
to the CNS. Patients with mutations in the TLR-3 pathway exhibit a greater 
susceptibility to herpes simplex encephalitis (HSE) compared to those with 
normal TLR-3 function (Guo et al., 2011; Herman et al., 2012; Lafaille et al., 
2012; Reinert et al., 2012; Zhang et al., 2007). Mice treated with 
polyinosinic:polycytidylic acid (Poly:IC), a potent TLR-3 agonist, are also 
protected from HSE following intranasal challenge (Boivin et al., 2008). 
During the course of viral latency, virus-specific T cells appear to play a key role 
in maintaining the virus in the latent state. There is an inverse relationship 
between the number of CD8+ T cells in the trigeminal ganglia and rate and extent 
of reactivation from latency as determined in a number of  animal model systems 
(Hoshino et al., 2007). Virus-specific CD8+ T cells surrounding latently infected 
ganglia form immunological synapses with polarization of pre-formed granules 
(Khanna et al., 2003). Treatment with anti-CD8 antibodies accelerates the rate of 
reactivation from trigeminal ganglia explants in murine models (St Leger and 
Hendricks, 2011) pin-pointing the importance of this immune cell population in 
controlling viral latency and reactivation.  In this regard, hormonal imbalance and 
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stress are common triggers of HSV-1 reactivation and have been shown to 
reduce the function of CD8+ T cells (Curtin et al., 2009; Freeman et al., 2008; 
Glaser and Glaser, 1998; Webster Marketon and Glaser, 2008). Taken together, 
these observations have been at the epicenter with respect to formulating 
mechanistic studies to examine the immunologic role of the CD8+ T cells in 
regulating the pathway from viral latency to reactivation and recurrent disease. 
There are numerous animals models which have been used to study 
infection, pathology, and immune responses of the eye, flank skin, and genital 
tract as previously reviewed (Kollias et al., 2014). The primary models used for 
studying immune responses to the HSV-1 have centered on the use of the 
mouse model that has involved the use of inbred, outbred, transgenic, mutated, 
and humanized mouse strains that vary in their degrees of susceptibility to HSV-
1 infection. Mice of different genetic backgrounds, as well as genetically distinct 
HSV-1 isolates have been used to study numerous stages of HSV-1 infection, 
making results published by different investigators often difficult to interpret 
and/or compare. The ocular scarification model has been shown to be very 
effective at eliciting a strong immune response in the trigeminal ganglia that is 
likely involved in controlling the virus during the course of viral latency. However, 
there are far fewer studies performed in the mouse system to study infection and 
pathology of the virus in the lip, one of the most common forms of HSV-1 
infection in the human population.  A lip model was described in a series of 
papers in the 1980’s (Kastrukoff et al., 1981), which has recently been used to 
determine the immune cell subsets required to restrict viral entry into the CNS of 
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C57BL/6 mice (Kastrukoff et al., 2010) and to map an NK-mediated locus of 
resistance that affects HSV-1 entry into the brain of adult mice (Kastrukoff et al., 
2015) . This model compromises the epithelial barrier by abrading the outside of 
the lip, originally accomplished with a wooden spatula (Kastrukoff et al., 1982). 
The compromised barrier allows for a somewhat more direct access of the virus 
to the keratinocytes in the epithelium to establish infection. We propose that this 
model will continue to be another important tool in understanding HSV-1 
replication and pathology in another anatomically important and commonly 
encountered tissue site where the majority of new HSV-1 infections are initiated. 
Consequently, we have defined the kinetics of HSV-1 replication and pathology 
in a susceptible strain of mice infected using the lip scarification model initially 
pioneered by Kastrukoff and colleagues now more than three decades ago to lay 
the foundation for the continued use of this model in studies to define the 
immune and therapeutic control of acute, latent, and recurrent infection and in 
studies to prevent, treat, and cure HSV infection. 
 
2.3. MATERIALS AND METHODS 
2.3.1. Virus, cells, and mice.  
Plaque-purified isolates of HSV-1 strain McKrae (Hill et al., 1987) were 
grown in Vero cell monolayers in Dulbecco's Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum (FBS). Cells were grown at 37°C in the 
presence of 5% CO2. Wild-type C57BL/6 adult (procured at 12 weeks of age) 
male mice were purchased from Jackson Laboratories. All animal experiments 
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adhered to procedures and guidelines approved by the Institutional Animal Care 
and Use Committee (IACUC) of Drexel University. Mice were anesthetized with 
Avertin and the lower lip scarified with 10 vertical strokes of a 25-gauge needle 
covering an area approximately 5 mm2.  A viral inoculum of 6.0×105 plaque 
forming units (PFU) suspended in 10 µL of MEM was applied to the lower lip and 
allowed to adsorb for 1 hour. The mice were observed during the duration of 
anesthesia. Vero cell lysate, applied at a volume equal to the virus inoculum, was 
used as a vehicle control.  
2.3.2. Titration of virus in tissue 
At indicated time points mice were euthanized by CO2 asphyxiation. The 
lower lip and TG were removed, weighed, and frozen in MEM containing 10% 
FBS. The tissue was stored at -80°C until ready for processing. The frozen tissue 
was subjected to three freeze-thaw cycles, homogenized, and resuspended in 
200 µL of serum-free MEM. The tissue homogenate was serially diluted in serum 
free MEM and then applied over a permissive Vero cell monolayer for viral 
quantitation studies. Virus was allowed to adsorb for 1 hour at 37°C and then 
Iscove's Modified Dulbecco's Medium (IMDM) and FBS (2%) in methylcellulose 
(1.5%) was added to the culture. The monolayer infection was allowed to 
proceed at 32°C for 4 days; the plates were fixed and stained with crystal violet 
(1%). Individual plaques were counted and the final PFU was determined. The 
final PFU was normalized to the mass of the collected tissue for a final value of 
PFU per gram of tissue. 
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2.3.3. Macroscopy of lower lip 
Mice were sacrificed at the indicated time points. The lower lips were 
visualized using a Leica EZ4HD stereo microscope at magnification factors of 0.8 
and 3.0.  
2.3.4. Histology  
Mice were sacrificed at the indicated time points. The lower lips and TG 
were dissected and fixed in 4% formaldehyde for 24 hours. The tissues were 
transferred to 70% ethanol (EtOH), cleared, infiltrated, and embedded in paraffin. 
Sections were cut to a thickness of 4 µm and stained with hematoxylin and eosin 
(H&E) dyes (Malatesta, 2016) .Tissue processing and sectioning was performed 
by the pathology diagnostics laboratory at the Drexel University College of 
Medicine. Images were obtained with an Olympus IX81 microscope running 
CellSens Dimension version 1.13. 
2.3.5. Immunohistochemistry of lip and TG sections 
Tissue from mice sacrificed at the indicated time points were 
deparaffinized, cleared, and rehydrated. Heat-induced epitope retrieval was 
performed with sodium citrate buffer (10 mM, pH 6.0). Lip sections were treated 
with primary antibodies rat anti-mouse CD45 (30-F11-Tonbo) and rabbit anti-
HSV-1 (Abcam) followed by overnight incubation at 4°C. Trigeminal ganglia 
sections were reacted with rat anti-mouse CD45 and rabbit anti-Neun 
(EPR12763-Abcam). T cells were detected in the lip using antibodies against 
CD3 (clone CD3-12 from Abcam), CD4 (clone 4SM95 from eBioscience) and 
CD8 (clone 4SM12 from eBioscience). T cells in the TG were detected using 
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monoclonal antibodies against CD4 (clone 15B12 from eBioscience) and CD8 
(clone 4SM16 from eBioscience). Isotype matched antibodies which are non-
specific for the antigens of interest were used for negative control experiments.  
Goat anti-rat Alexa 555 (Molecular Probes®) and Goat anti-rabbit Alexa 488 
(Molecular Probes®) conjugated secondary antibodies were used for detection. 
Nuclei were counterstained with DAPI (Invitrogen). Sections were visualized 
using an Olympus IX81 fluorescent microscope running CellSense Dimension 
version 1.13. 
2.3.6. Genome copy number 
Mice were sacrificed at the indicated time points. The lower lip and TG 
were dissected and frozen in RNAlater® RNA stabilization reagent (Thermo 
Fisher). The tissue was thawed and genomic DNA isolated using the GenElute™ 
Mammalian Genomic DNA Miniprep procedure as described by the manufacturer 
(Sigma Aldrich). Quantitative-PCR (qPCR) was performed using custom Taqman 
(Invitrogen) probes against the thymidine kinase gene (forward: 
GGCCCCCAACACGATGT, reverse: CGTGCTGGCGTTCGT) from the HSV-1 
McKrae strain (accession: JX142173). Vero cells were infected with HSV-1 
McKrae at an MOI of 0.01 and harvested after 48 hours. The PFU per mL of virus 
lysate was determined using a standard plaque assay and the genomic DNA of 
the virus lysate isolated as above. The virus lysate DNA was serially diluted and 
used to generate a standard curve for the qPCR reaction. The experimental 
sample cycle thresholds were interpolated and plotted on the standard curve 
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using GraphPad prism version 6.0. Genome copy numbers were made relative to 
the mass of isolated tissue to generate a genome per gram tissue value. 
2.3.7. Poly:IC stimulation 
High molecular weight Polyinosinic:polycytidylic acid (Poly:IC - Invivogen) 
was suspended in 10 mL of sterile water to a concentration of 1 mg/mL. Mice 
were stimulated with 100 µg of Poly:IC by IP injection  or 10 µg of Poly:IC by 
direct injection into the lower lip 24 hours prior to infection. Sterile saline was 
used as vehicle control for Poly:IC.  Mice were then infected with 6.0×105 pfus of 
HSV-1 McKrae. The mice were sacrificed 5 days post-infection and the lower lip 
harvested. The presence of cell free virus was assayed by plaque assay as 
described above.  
2.3.8. Statistics 
All statistics were done using GraphPad prism version 6.0. 
 
 
2.4. RESULTS 
2.4.1. Infected mice exhibit skin lesions similar to those in human 
infections 
A majority of new HSV-1 infections in humans occur in the orofacial tissue, 
yet there are few available animal models for studying primary, latent, and 
reactivated infection in peripheral tissues and nerve tracts associated with the 
oral cavity and surrounding tissues. As one experimental approach to facilitate 
continued advancement of knowledge concerning this area of HSV-1-associated 
81 
 
pathogenesis and disease, the lip scarification model (Kastrukoff et al., 1981; 
Kollias et al., 2014) has used a needle to compromise the external barrier of the 
lip prior to experimental application of virus to the scarified area to consistently, 
and reproducibly initiate the infection. To this end, the lower lip was scratched 
using a 25-gauge needle (Fig. 2.1.A). Based on prior observations (Kastrukoff et 
al., 1988), this experimental protocol has been shown to deliver virus to cells in 
the epithelial and subepithelial regions of the lip. The virus gains access to 
sensory nerves with subsequent translocation of virus in the retrograde direction 
towards the trigeminal ganglia (TG) via the mandibular nerve branch (Fig. 2.1.B). 
After inoculation with vehicle or virus, mice were sacrificed at the indicated 
time points and the lower lip was subjected to pathological examination. The 
untreated and vehicle exposed mice showed no signs of skin pathology (Fig. 
2.1.C). Virus-infected animals exhibited erythematous vesicular lesions present 
on the lower lip on day 5 post-infection (second row). There were also initial 
signs of crusting over of the lesions. The lesions were still healing 8 days post-
infection (third row) and had completely resolved by 15 days post-infection (last 
row). These results closely resemble the time course of human disease which 
has vesicular lesions in the first week that usually resolve during the second 
week.  
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Figure 2.1.  Infected mice display clinical lesions. (A) Schematic of lip 
scarification with vertical scratches. Dashed lines indicate location of scratches 
(left). Image of mouse lip from the same location modeled in the cartoon (right). 
(B) Cartoon of the mouse trigeminal ganglia with sensory branches labeled. (C) 
Macroscopic image of the mouse lip untreated (top) or scratched and inoculated 
with either vehicle (left) or 6*105 PFU of HSV-1 McKrae (right). At indicated time 
points, mice were sacrificed and the lower lips imaged using a dissection 
microscope. One experiment with n=3 mice. 
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Figure 2.1. 
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2.4.2. Infected lips display histopathology associated with HSV-1 infection 
In order to demonstrate that the skin lesions contained cytological 
pathology consistent with HSV-1 infection, samples were also processed for 
histological examination. The unexposed lower lip showed a thin epidermis that 
was 1-2 cells thick. Underlying the epidermis was the dermal layer containing 
dense collagen fibers, elongated fibroblasts, and resident leukocytes (Fig. 2.2.A). 
In the hypodermis layer were hair fibers, muscle fibers, sebaceous glands and 
adipocyte deposits. In mice exposed to the vehicle, a thickening of the epidermis 
(acanthosis) and infiltration of inflammatory cells were observed. Crust formation 
was also observed over the site of epidermal thickening and inflammatory cell 
infiltration.  There was no extensive damage to the epidermal or dermal layers of 
the lip when exposed to the vehicle (Fig. 2.2.B, left). Mice infected with HSV-1 
showed extensive damage in the epidermal and dermal layers. Multi-nucleated 
cell bodies containing epithelial cells with chromatin margination and cellular 
bodies lacking chromatin material (orthokeratosis) were observed in the animals 
exposed to virus (Fig. 2.2.B, right).  
Mice exposed to vehicle alone for 5 days continued to show epidermal 
thickening and inflammation, but no additional damage to the dermis or 
epidermis (Fig. 2.2.C, left). However, mice exposed to virus preparations showed 
areas of complete epidermal destruction. The lesions were covered with a very 
thick layer of crust. The crust was composed of proteinaceous material, 
degenerated keratinocytes, and necro-inflammatory debris. Immediately below 
the crust, the dermis was severely disrupted with many dying and dead cells 
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containing Cowdry type A nuclear inclusion bodies (Fig. 2.2.C, right). By day 8 
post-infection, mice infected with virus showed signs of recovery and healing. A 
smaller thickness of crust was observed over areas of healing. Areas of healing 
had a restored epidermal layer that was very thick indicating epidermal 
hyperplasia. However, cellular inflammation persisted beneath the thickened 
epidermal layers. Apoptotic bodies could be observed, but in lower numbers than 
observed at earlier time points (Fig. 2.2.D, right).  
At 15 days post-infection, the epidermal layer still appeared thick. In 
contrast to the lips observed on day 8, the thickness was due to numerous cell 
layers and not hyperplasia of the epidermal cells. A strong inflammatory infiltrate 
remained in the lip (Fig. 2.2.E, right). These results indicate that during the active 
primary infection in the skin, initial replication occurs in the epidermal layer. As 
the infection proceeds, destruction of the epidermal layer and disruption of the 
dermis occurs and is covered by a thick crust. Immune cell infiltration was 
observed at the site of infection. Pathology is limited to the epidermal and dermal 
layers; no pathology could be observed in the hypodermis. By day 8, the 
epidermal layer was restored with the remaining pathology observed as a thick 
area of epithelial hyperplasia. By day 15 post-infection, the lesion consisted of a 
thickened epidermis with signs of inflammation. 
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Fig. 2.2. Histopathology of lips infected with HSV-1. Mice were scratched and 
inoculated with either vehicle (left) or 6.0×105 PFU HSV-1 McKrae (right). (A-E) 
at indicated time points, mice were sacrificed and the lips processed for 
histological sectioning and staining. Arrowheads point to regions of interest that 
are highlighted by high power insets at 40X or 100X magnification. One 
representative experiment with n=3 mice. 
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Figure 2.2. 
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To correlate pathology in the lip with presence of virus replication, 
microscopic immunohistochemistry was used to detect viral antigen and 
demonstrate immune cell infiltration into the lip tissues infected with HSV-1. A 
polyclonal antibody preparation directed against HSV-1 (Abcam) was used in 
conjunction with an anti-CD45 monoclonal antibody (clone 30-F11, provided by 
Tonbo). CD45, a protein tyrosine phosphatase receptor that has been shown to 
be found on all hematopoietic cells, was used to identify leukocytes. The 
unexposed lip contained no viral antigen and few CD45+ cells in the dermal layer 
of the lip (data not shown). In mice infected with HSV-1, large amounts of viral 
antigen were observed in the epidermal layer in mice at day 2 post-infection (Fig. 
2.3.A). We were able to correlate viral antigen-positive cells with DNA staining 
pattern indicating chromatin margination. We also observed viral antigen in the 
hypodermal layer in hair follicles. At day 2 post-infection, CD45+ cells were 
observed in close proximity to areas also containing HSV-1 antigen, as 
determination immunohistochemistry. At day 5, HSV-1 antigen was diminished 
and largely limited to the dermal layer below the crust. Dense areas of viral 
antigen were observed in hair follicles of the hypodermis. There was also a large 
accumulation of CD45+ cells surrounding the HSV-1 antigen-positive hair follicles 
(Fig. 2.3.B). On day 8, no viral antigen was observed in the lip. However, large 
accumulations of CD45+ cells were observed in areas of epithelial hyperplasia at 
this time point (Fig. 2.3.C). Finally, on day 15 post-infection, no viral antigen was 
present, but there were still numerous CD45+ inflammatory cells present in the 
lip. (Fig. 2.3.D). These results demonstrated that the pathology present in the lip 
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was closely associated with the presence of viral antigen. Early in the infection, 
there was clear presence of viral antigen and detectable virus-induced pathology 
in the lip. However by day 8, no viral antigen was present in the lip and no 
pathology was observed in the lip. The remaining immune cells detected at day 
15 represented the final stages of the healing process and the area that 
previously supported viral replication during acute primary infection.  
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Figure. 2.3. Infected mice display HSV-1 antigen in the lower lip. Mice were 
exposed to vehicle (left) or 6.0×105 PFU of HSV-1 McKrae (right). (A-D) Mice 
were sacrificed at indicated time points and processed for histological sectioning. 
Sections were reacted with antibodies against HSV-1 (green) and CD45 (red) 
and counterstained with DAPI (blue). Arrowheads point to regions of interest 
highlighted by high power panels. One experiment with n=3 mice. 
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Figure 2.3. 
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 The adaptive immune response plays an important role in resolving the 
primary infection in the periphery. CD4+ T-helper cells coordinate immune 
responses to clear viral infections while CD8+ cytotoxic T cells directly caused 
apoptosis of infected cells. Antibodies specific for T-lymphocyte markers were 
used to detect the presence of CD4+ T cells and CD8+ T cells in the lip. 
Preparations of polyclonal antibodies against HSV-1 and monoclonal antibodies 
against CD4 (clone 4SM95 provided by eBioscience) or CD8 (clone 4SM15 from 
eBioscience) were used on lip sections from mice harvested 15 days post-
infection. This time point is after resolution of the primary infection in the lip (Fig. 
2.7.) but it is anticipated that responding adaptive immune cells would still be 
present. Immunohistochemistry revealed a large population of CD4+ T cells in the 
lip still present in the lip. CD4+ T cells were found in close proximity to hair 
follicles and throughout the dermis layer (Fig. 2.4., top). There was a smaller 
population of CD8+ T cells in the lip which appeared to be predominantly in the 
epidermal layer, but some were also near hair follicles (Fig. 2.4., bottom). There 
was no HSV-1 antigen straining present which confirmed that the peripheral 
infection had been resolved by 15 days post-infection.  
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Figure 2.4. CD4+ and CD8 T cells were shown to be present in the lower lip. 
Mice were treated with 6.0×105 PFU HSV-1 McKrae and then sacrificed 15 days 
post infection. Tissue sections were treated with antibodies against HSV-1 
(green) and CD4 or CD8 (red) and counterstained with DAPI (blue). One 
experiment with n=3 mice.  
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Figure 2.4. 
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Infection of innervating sensory neurons in the periphery leads to 
establishment of latency in the TG as shown previously (Hill et al., 1975). The TG 
is infiltrated with immune cells and eventually HSV-1-specific T cells are 
observed surrounding latently infected neurons. Consistent with these previous 
observations, sections of TG were prepared at increasing time points after the 
initial infection of the lip to determine if immune cells infiltrate the nerve following 
lip scarification and virus inoculation. The TG tissue derived from untreated and 
control animals exposed to vehicle alone showed a large amount of cellularity 
from satellite cells and Schwann cells (Fig. 2.5). However, beginning on day 5 
post-infection, a large increase in the number of immune cells was observed in 
the nerve and those immune cells that were observed were associating with 
neuronal cell bodies (Fig. 2.5, arrowheads). Immunohistochemistry utilizing 
monoclonal antibodies directed against CD45 demonstrated that these cells were 
of hematopoietic origin and likely immune cells responding to viral infection of 
innervating sensory neurons. Minimal immune cell infiltration was observed on 
day 2 post-infection; possibly reflecting the time it takes for the virus to travel 
retrograde from the sensory neuron axon innervating the lip to the neuronal cell 
body in the TG and the time for the immune response to get deployed in the TG. 
The CD45+ cells remained in the TG through day 15 post-infection, some of 
which are CD3+ CD4+ or CD3+ CD8+ T cells which will be retained in the TG 
during latency (Fig. 2.6).  
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Figure 2.5. CD45+ cells infiltrate the trigeminal ganglia of infected mice. At 
indicated time points, the trigeminal ganglia from mice exposed to vehicle or 
6.0×105 PFU HSV-1 McKrae were processed for histological sectioning. The 
trigeminal ganglia were stained with H&E (left) or treated with antibodies (right) 
against Neun (green) and CD45 (red) and counterstained with DAPI (blue).  
Arrowheads point to regions where cellular infiltration is evident. One 
representative experiment with n=3 mice. 
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Figure 2.5. 
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Figure 2.6. CD4+ and CD8+ T cells infiltrate the trigeminal ganglia. Mice were 
infected with 6.0×105 PFU HSV-1 McKrae and then sacrificed 15 days post 
infection. Tissue sections were treated with antibodies against HSV-1 (green) 
and CD4 or CD8 (red) and counterstained with DAPI (blue). One representative 
experiment with n=3 mice.  
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Figure 2.6. 
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2.4.3. HSV-1 replicates in the lip before establishing latency in the 
trigeminal ganglia 
To determine the time frame of viral replication in both the lip and TG, 
mice were sacrificed at indicated time points and tissue was subsequently 
collected from the lip and TG. Peak virus replication (1.90×106 pfu/gram) was 
observed in lip tissue day 2 post-infection. This level of virus production in the lip 
continued to day 5 post-infection (2.0×106 PFU/gram) followed by a decrease in 
replication to undetectable levels by day 8. Virus replication in the TG was not 
evident until day 5 post-infection (peaking at 2.0×104 PFU/gram), correlating with 
the observed increase in infiltrating immune cells at this time point (Fig. 2.4, row 
5). At day 8, cell-free virus production was below the level of detection in the TG 
and remained so through the remainder of the time course (Fig. 2.7, left). 
While replicating virus decreased to undetectable levels, we hypothesized that 
there would still be viral genomes present in the TG. Genomic DNA was also 
isolated from the lips and TGs at the indicated times after infection to assay for 
viral genome copy numbers by quantitative PCR. High levels of HSV-1 genomes 
were present in the lip at days 2 and 5 post-infection, peaking at 1.5×105 genome 
copies per gram tissue. The number of viral genome copies decreased 
dramatically by day 8 but was still detectable at 8.0×103 copies per gram tissue. 
The number of viral genomes continued to decrease at day 15 but was still 
detectable at 6.0×103 copies per gram tissue in the lip (Fig 2.7, right). This was 
an unexpected result as cell-associated or cell-free infectious virus was no longer 
detectable after 5 days post-infection by plaque assay. The nature of the HSV-1 
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genomes detectable in the lip at later times post-infection will be future 
investigation in Chapter III.  Retention of the HSV-1 genome at peripheral sites in 
the absence of detectable viral infectivity in cell-free homogenates has been 
observed previously in ocular tissues and other peripheral sites (Higaki et al., 
2015).  
With respect to the TG, HSV-1 genome copies in the TG were detectable 
by day 2 post-infection. The number of detectable viral genome copies was 
shown to increase at day 5 and established an apparent base line around 
1.0×105 genome copies per gram tissue. The level of HSV-1 genome copy 
number retained in the TG was consistent at days 5, 8, and 15 post-infection 
(Fig. 2.7, right).  
Finally we tested the model by stimulating mice with the immunogenic 
molecule poly:IC. It has been established that patient’s harboring mutations in 
the TLR3 pathway have an increased susceptibility to herpes simplex 
encephalitis. Poly:IC has been used in animal models of herpes simplex 
encephalitis to protect animals from lethal challenge. Poly:IC is a synthetic 
double stranded RNA molecule which is a potent stimulator of the TLR3 pathway, 
which plays a role in anti-viral responses in the immune response. Activation of 
the TLR3 pathway leads to induction of the antiviral state in uninfected cells and 
secretion of interferons which would initiate the antiviral response of the innate 
immune system. Given this, poly:IC was used prior to infection to determine if 
treatment would aid in clearance of infectious virus.  
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Mice were treated with 100 µg of poly:IC suspended in water 24 hours 
prior to infection. Mice were sacrificed 5 days post-infection and the tissue 
analyzed for infectious cell free virus. Mice which were treated via intraperitoneal 
injection had a mean viral load of 1.4×106 pfus per gram of tissue compared to 
4.0×105 pfus per gram tissue in the saline treated animals. This indicates that 
there was no significant reduction in virus replication in the lip. It is possible that 
systemic administration of the poly:IC did not appreciably activate antiviral 
immune responses in the lower lip where the virus was administered and 
replication occurred. We treated mice with 10 µg of poly:IC injected directly into 
the lower lip prior to viral infection. Mice were harvested 5 days post-infection 
and the tissue valuated for infectious cell free virus. The mean viral load in the 
lips of these mice was 1.3×106 pfus per gram tissue compared to 6.2×105 pfus 
per gram tissue in saline treated animals.  
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Figure 2.7. Kinetics of HSV-1 replication in the lip and trigeminal ganglia of 
infected mice. Mice were infected with 6×105 PFU HSV-1 McKrae. At indicated 
time points, the lip and trigeminal ganglia were isolated and analyzed for 
infectious virus by plaque assay (left) and viral genome copies by qPCR (right). 
The dotted line indicates limit of detection by plaque assay. PFU and genome 
copy values were made relative to the mass of the tissue analyzed. Closed 
squares indicate results obtained with lip tissue. Open circles represent the 
results obtained in trigeminal ganglia tissue.  Data are from 1 experiment with 
n=5 mice per time point.  
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Figure 2.7. 
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Figure 2.8. Treating mice with poly:IC prior to infection does not reduce 
virus replication in the lip. Mice were treated with poly:IC 24 hours prior to 
infection. Mice were treated with intraperitoneal (IP) injection of 100 ug (left) or 
direct lower lip injection of 10 ug (right) of poly:IC. The mice were sacrificed and 
the lower lips harvested 5 days post-infection. These data are from 1 experiment 
n=4 mice per group (left) or 5 mice per group (right).  
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Figure 2.8. 
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2.5. DISCUSSION 
The first reported usage of the lip model was in 1981 (Kastrukoff et al., 
1981) and was later modified to some extent by initiating HSV-1 infection by 
abrasion of the mouse lip with a wooden spatula (Kastrukoff et al., 1982). The lip 
infection model has been used successfully to study HSV-1 entry into the CNS, 
HSV-1-induced demyelination (Kastrukoff et al., 1988), and genetic resistance to 
HSV-1 encephalitis in different strains of laboratory animals (Kastrukoff et al., 
2012). These studies demonstrated that using this model, mice could be 
successfully infected with HSV-1 and that virus could gain access to the CNS as 
well as the TG. These studies did not seek to define the kinetics of viral 
replication or the corresponding immune responses in the lip or peripheral 
nervous system. However, to date, the model has not been widely adopted and 
instead, most studies involving HSV-1 pathogenesis have used the flank, foot-
pad, or ocular scarification model for studying virus replication and pathogenesis 
as well as the associated immune responses. Because most new human HSV-1 
infections occur in the oro-facial mucosa and surrounding epithelial tissues, we 
propose that the lip inoculation model would be very physiologically relevant for 
studying human disease caused by HSV-1. In order to validate the model for 
studying human disease, we first sought to define the viral replication kinetics, 
host pathology, and immune response to viral HSV-1 infection.  
It was clear that the scarification of the lip did not cause severe or lasting 
damage to the lip both macroscopically and microscopically (Fig. 2.1 and 2.2). 
Erythematous lesions were observed in the lower lip in virus-infected animals 
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that were very similar to what has been observed previously in humans with 
primary infection (Arduino and Porter, 2008). Histopathological examination (Fig. 
2.2) and immunohistochemistry (Fig. 2.3) demonstrated the presence of HSV-1 
antigen in the lip with related pathology in the epidermis. A strong inflammatory 
infiltrate was observed at all points during the acute infection. It was very evident 
from the accumulated HSV-1 antigen and CD45+ staining during the course of 
infection that the hair follicles were a prominent site of HSV-1 infection in the lip. 
Hair follicles have been shown to be innervated to induce secretion of sebum and 
contraction of erector pili. The presence of HSV-1 in the innervated hair follicles 
could represent a route of infection involving the peripheral nervous system 
outside of the sensory axons leading to the trigeminal ganglia. The kinetics of 
viral infection, replication, and pathogenesis were very similar to what has been 
observed in cases of human infection where most of the pathology is observed in 
the first week, with the lesions subsequently healing and resolving during the 
second week. In general, the viral replication and pathogenic kinetics shown in 
the mouse lip infection model mirror the results previously reported with respect 
to clinical signs and symptoms of disease observed in humans.  This model 
could also be used for examining the pathology associated with HSV-1 infection 
of the oral tissue.  Furthermore, this model would be extremely useful for 
studying new anti-viral compounds and their impact on reduction of viral 
replication, pathology, and inflammatory responses prior to clinical trials in 
humans.  
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As one of the key features to our experimental approach, C57BL/6 mice 
were selected as the target mouse strain because these animals have been 
shown to be one of the most resistant strains of mice with respect to viral entry 
into the CNS that often leads to a fatal encephalitic disease. Furthermore, adult 
mice were selected, to ensure a mature and competent immune system that 
facilitates the survival of primary disease and the establishment of a latent 
infection. The HSV-1 McKrae strain was selected because it represents a viral 
strain that has previously been shown to be neuroinvasive. The combination of a 
highly immunocompetent adult mouse with a genetic background including a high 
resistance to HSV-1 CNS viral penetration infected with the neuroinvasive 
McKrae strain of HSV-1 previously shown to be able to penetrate the peripheral 
nervous system has led to efficient entry of virus into the mouse TG subsequent 
to a mouse lip infection with the subsequent establishment of latency within the 
context of a robust immune system facilitating survival in the absence of CNS 
disease. Replicating virus was readily observed in the lip and TG that resolved by 
8 days after initial infection.  A similar pattern of viral replication was observed in 
the lip utilizing a qPCR assay designed for the detection of viral copies of the TK 
gene. However, instead of complete clearance of detectable viral genomes as 
determined by the quantitation of the TK gene in the lip, detectable genome 
copies remained at 8 and 15 days post-infection. This observation was 
somewhat unexpected since we theorized that along with resolution of pathology 
and replicating virus, intact viral nucleic acid would no longer be detected in lip 
tissues after the disappearance of viral infectivity. This result has suggested the 
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possibility of either low level long-term viral genome persistence in the lip in the 
absence of cell-free viral infectivity or non-neuronal latency in the lip. There have 
been numerous studies exploring the possibility that HSV-1 persists in a “latent 
state” within corneal tissues. Corneal transplants are a common procedure and 
have restored vision to numerous individuals. However there is evidence of 
transmission of HSV-1 from the corneas of infected individuals to HSV-1-
negative transplant recipients (Higaki et al., 2015; Kaye et al., 1991). Corneal 
epithelial cells have been shown to be capable of supporting in vitro latency 
(Cook and Brown, 1986). 
The lip model has also been shown to be useful for studying selected 
aspects of the immune response to viral infection as well as immunologic events 
post viral clearance. We detected CD4+ and CD8+ T cells in the lip 15 days post-
infection (Fig. 2.4). Some of these cells will likely die during the immune cell 
contraction phase, but others will remain long lived in the lip where the virus was 
initially encountered. Lip tissue sections at 30 days post-infection have confirmed 
the retention of these cells long after the resolution of primary infection. 
Monoclonal antibodies which can detect CD4 and CD8 in formalin fixed paraffin 
embedded mouse tissue have only recently become available. It is believed that 
formaldehyde fixation damages the CD4 and CD8 antigens to a point that 
previously available antibody formulations were unable to detect them in paraffin 
embedded tissue. Extensive work has been performed to evaluate epitope 
retrieval techniques to make the antigen available, but to date the results have 
been unsatisfactory (Kim et al., 2004a, 2004b). There is compelling evidence that 
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virus-specific CD8+ T cells play an important role in maintaining the virus in a 
noninfectious latent state. In addition, the virus-specific CD8+ T cells in the TG 
belong to a recently described class of tissue resident memory T cells (TRM) 
(Himmelein et al., 2011). The virus travels by retrograde flow from a peripheral 
site during primary infection to the TG where it establishes latency. We have 
observed CD3+, CD4+, and CD8+ T cells in the TG 15 days post-infection (Fig. 
2.6). These cells were dispersed in the TG and commonly found adjacent to 
neurons.  We have also shown that the available clones for detecting CD4 (4SM9 
from eBioscience) and CD8 (4SM15 from eBioscience) were producing non-
specific staining of neuronal cell populations in the TG. Additional clones 
provided by eBioscience were able to detect the CD4 and CD8 antigens in the 
TG without the non-specific staining. The presence of these cells confirms the 
usefulness of the lip model for studying T cells responses to HSV-1 infection in 
the TG. We have been able to isolate and perform flow cytometry on immune 
cells from the TG following lip scarification and infection (data not shown). The 
role that immune cells play in maintaining the virus in a latent state is important 
for understanding the triggers of reactivation. Many common triggers including 
hormone imbalance and stress have inhibitory effects on CD8+ T-cell function 
(Freeman et al., 2008; Sinani et al., 2013). Drugs that alter the immune system 
for treatment of other systemic conditions like rheumatoid arthritis (RA), chronic 
ulcerative colitis, and chronic plaque psoriasis could have negative 
consequences on the immune system’s ability to control acute and recurrent 
infections (Bradford et al., 2009). The host pathogen interactions resulting from 
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treatment with drugs which specifically target immune cell responses can be 
explored using this model of infection.  
For decades, investigators have been searching for a potential 
prophylactic or therapeutic vaccine for HSV-1. Recent work has shown that gD 
null (Wang et al., 2016) and gK null (Iyer et al., 2013) mutants might provide 
strong immunity against lethal HSV challenges in animal models. It would be 
useful to determine whether these potential vaccine candidates work in a 
physiologically relevant animal model system where a low to moderate dose of 
virus would be applied permitting the animal to recover from the acute infection. 
The efficacy of these vaccines to prevent or reduce the establishment of latency 
and recurrent infection could be studied with the HSV-1 lip scarification mouse 
model.  
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3.1. ABSTRACT 
Lip scarification has been successfully used to model the acute events of 
HSV-1 infection in oral mucosa as well as the surrounding epithelial tissues. Here 
the lip scarification is used to model HSV-1 establishment of latency and 
reactivation in the laboratory mouse. Adult mice were inoculated with HSV-1 after 
scarification and sacrificed 30 days later. No infectious virus could be found in 
the lip and trigeminal ganglia after 30 days. However, HSV-1 genomes were 
detectable in the TG and expression of the major LAT transcript was detected. 
CD4+ and CD8+ T cells were detected in the area of the lip where mice were 
inoculated as well as in the trigeminal ganglia. Latent HSV-1 genomes in the 
trigeminal ganglia reactivated from latency when single cell TG suspensions 
were cocultured with indicator cells. Interestingly, the lip tissue was also capable 
of reactivating from latency when cocultured with indicator cells. These novel 
results could be indicative of peripheral latency with virus capable of reactivation 
from a peripheral site in standard co-cultivation assays under conditions where 
infectious was not detectable in cell-free homogenates.  
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3.2. Introduction 
Herpes simplex virus type 1 (HSV-1) is a ubiquitous human pathogen that 
is endemic worldwide (Xu et al., 2006). The herpesviruses are unique in their 
ability to establish latent infections which persist for the lifetime of the host. 
During primary infection in the periphery, the virus infects sensory neurons 
innervating the peripheral tissue. The virus travels in a retrograde direction to 
replicate in cells of the trigeminal ganglia (TG). Following activation of the 
adaptive immune system, the replicating virus is cleared from the periphery and 
TG. With clearance of the acute infection, no replicating virus can be found in the 
peripheral tissue or TG, and virus is not actively being shed from infected 
individuals (Schulte et al., 2014). However, with exposure to certain triggers, the 
virus can reactivate from latency and replicate within the TG, traveling back down 
the axons to the periphery to replicate in epithelial cells and cause recurrent 
disease.  
The latent virus is maintained in the nucleus of infected neurons. The viral 
genome persists as an episome which is bound up with nucleosomes bearing 
heterochromatin markers (Efstathiou et al., 1986a). During latency, no abundant 
viral gene expression is detected with the exception of the latency-associated 
transcript (LAT). The LAT is an 8.3 kb species which is processed to produce a 2 
kb major LAT and 6.3 kb minor LAT species (Javier et al., 1988; Wagner et al., 
1988). The minor LAT species is further processed to make microRNAs (miRNA) 
which bind to and reduce expression of viral lytic genes (Jurak et al., 2012; Pan 
et al., 2014; Schlee et al., 2009; Umbach et al., 2008). The major LAT transcript 
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functions to promote survival of the latently infected cells which are surrounded 
by virus-specific CD8+ T cells in the trigeminal ganglia (Branco and Fraser, 
2005). LAT appears to also be necessary for efficient reactivation from latency, 
though the mechanisms through which it accomplishes these functions are 
currently unknown.  
There are numerous in vitro and in vivo models used to study latency in 
reactivation. In vitro systems range from quiescently infected fibroblasts to 
infection of neuronal cell lines (Scheck et al., 1989; Wigdahl et al., 1984, 1983, 
1982a, 1982b, 1981). However, most in vitro systems require an unnatural 
repression of virus replication with either anti-viral drugs or mutant viruses 
lacking lytic genes to induce a latent state (reviewed in (Scheck et al., 1986; 
Wigdahl et al., 1982a) . Rabbit animal models of reactivation are popular 
because iontophoresis treatment of the eye reproducibly initiates reactivation. 
Reactivated virus can also be readily detected from tear swabs and do not 
require sacrifice and harvest of infected tissue (Cook et al., 1987). Unlike rabbits, 
the laboratory mouse does not undergo spontaneous reactivation (Feldman et 
al., 2002). However in vivo reactivation has been achieved using stressors such 
as hyperthermia, restraint stress, and hormonal injections as previously reviewed 
(Kollias et al., 2014)). The mouse has also led to numerous ex vivo model 
systems which involve plating explanted TG in culture. The explanted cultures 
reactivate from the stress of being surgically removed from the animal. The 
timing of reactivation can be altered with addition of nerve growth factor (NFG) 
(Wilcox et al., 1990; Wilcox and Johnson, 1987) or anti-CD8 antibodies (Khanna 
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et al., 2003). This has led to insights into how the function of CD8+ T cells in the 
TG and neuronal health affect the regulation of reactivation.  
The mouse latency models principally focus on the eye and flank as sites 
of infection. However, most new human infections above the neck occur in the 
orofacial tissue. We recently characterized the replication kinetics and pathology 
of HSV-1 infection in the lip scarification model. This model uses a topical 
application of HSV-1 to the scratched lip of anesthetized mice (Kastrukoff et al., 
1986). The virus replicates in the lip, and clinical lesions consistent with human 
infections have been observed. The virus gains access to sensory nerves and 
subsequently the TG. The immune response infiltrates infected tissues and 
clears replicating virus from the lip and TG. However, viral genomes can still be 
detected in the TG after resolution of the primary infection. Here we evaluate the 
lip scarification model for studying HSV-1 latency and reactivation in a mouse 
model.  
Scarified mice were infected and then harvested 30 days post-infection. 
We detected latent genomes in the TG and related LAT expression. Explanted 
TGs were capable of reactivating from latency in culture, and infectious HSV-1 
can be recovered by explanted cocultivation. Interestingly, explanted lips were 
also capable of reactivating from latency utilizing similar procedures. These 
surprising results shed new light on the nature of HSV-1 latency and reactivation 
in the periphery. 
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3.3. MATERIALS AND METHODS 
3.3.1. Virus, cells, and mice 
Plaque-purified isolates of HSV-1 strain McKrae (Hill et al., 1987) were 
grown in Vero cell monolayers in Dulbecco's Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum (FBS). Cells were grown at 37°C in the 
presence of 5% CO2. Wild-type C57BL/6 adult (procured at 12 weeks of age) 
male mice were purchased from Jackson Laboratories. All animal experiments 
adhered to procedures and guidelines approved by the Institutional Animal Care 
and Use Committee (IACUC) of Drexel University. Mice were anesthetized with 
Avertin and the lower lip scarified with 10 vertical strokes of a 25-gauge needle 
covering an area approximately 5 mm2.  A viral inoculum of 6.0×105 PFU 
suspended in 10 µL of DMEM was applied to the lower lip and allowed to adsorb 
for 1 hour. The mice were observed for the duration of anesthesia. Vero cell 
lysate, applied at a volume equal to the virus inoculum, was used as a vehicle 
control.  
3.3.2. Titration of virus in tissue 
At indicated time points, mice were euthanized by CO2 asphyxiation. The 
lower lip and TG were removed, weighed, and frozen in DMEM containing 10% 
FBS. The tissue was stored at -80°C until ready for processing. The frozen tissue 
was subjected to three freeze-thaw cycles, homogenized, and resuspended in 
200 µL of serum-free DMEM. The tissue homogenate was serially diluted in 
serum-free MEM and then applied to permissive Vero cell monolayers for viral 
quantitation studies. Virus was allowed to adsorb for 1 hour at 37°C and then 
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Iscove's Modified Dulbecco's Medium (IMDM) and FBS (2%) in methylcellulose 
(1.5%) was added to the culture. The infection of the monolayer was allowed to 
proceed at 37°C for 4 days; the plates were fixed and stained with crystal violet 
(1%). Individual plaques were counted and the PFU was determined. The PFU 
was normalized to the mass of the collected tissue for a final value of PFU per 
gram of tissue.  
3.3.3. Histology 
Mice were sacrificed 30 days post infection and the lip and TG were 
surgically removed. The tissue was fixed in 4% formaldehyde for 24 hours, 
transferred to 70% ethanol, cleared, infiltrated, and embedded in paraffin. 
Sections were cut to a thickness of 4 µm and stained with hematoxylin and eosin 
(H&E) dyes (Malatesta, 2016). Tissue processing and sectioning was performed 
by the pathology diagnostics laboratory at Drexel University. Images were 
obtained with an Olympus IX81 microscope running CellSens Dimension version 
1.13. 
3.3.4. Immunohistochemistry of lip and TG tissue sections 
Processed and sectioned tissue from sacrificed mice were deparaffinized, 
cleared, and rehydrated. Heat-induced epitope retrieval was performed with 
sodium citrate buffer (10 mM, pH 6.0). T cells were detected in the lip using 
antibodies against CD3 (clone CD3-12 from Abcam), CD4 (clone 4SM95 from 
eBioscience), and CD8 (clone 4SM12 from eBioscience) combined with a 
polyclonal antibody against HSV-1 (Abcam).  T cells in the TG were detected 
using monoclonal antibodies against CD3 (clone 3D3-12 from Abcam), CD4 
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(clone 15B12 from eBioscience), and CD8 (clone 4SM16 from eBioscience). 
Neuronal cell bodies were detected using a monoclonal antibody specific for 
Neun (clone EPR12763-Abcam). All the primary antibodies were used at a 
concentration of 5 µg and incubated overnight at 4°C. Goat anti-rat Alexa 555 
(Molecular Probes®) and goat anti-rabbit Alexa 488 (Molecular Probes®) 
conjugated secondary antibodies were used for detection. Secondary antibodies 
were used at a concentration of 2 µg and incubated 1 hour at room temperature.  
Nuclei were counterstained with DAPI (Invitrogen). Sections were visualized 
using an Olympus IX81 fluorescent microscope running CellSense Dimension 
version 1.13. 
3.3.5. Genome copy number 
Mice were sacrificed at the indicated time points. The lower lip and TG 
were dissected and stored in RNAlater® RNA stabilization reagent (Thermo 
Fisher). The tissue was minced and genomic DNA isolated using the GenElute™ 
Mammalian Genomic DNA Miniprep procedure as described by the manufacturer 
(Sigma Aldrich). Quantitative-PCR (qPCR) was performed using custom Taqman 
(Invitrogen) probes against the thymidine kinase gene (forward: 
GGCCCCCAACACGATGT, reverse: CGTGCTGGCGTTCGT) from the HSV-1 
McKrae strain (accession: JX142173). Vero cells were infected with HSV-1 
McKrae at an MOI of 0.01 and harvested after 48 hours. The PFU per mL of virus 
lysate was determined using a standard plaque assay and the genomic DNA of 
the virus lysate isolated as above. The virus lysate DNA was serially diluted and 
used to generate a standard curve for the qPCR reaction. The experimental 
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sample cycle thresholds were interpolated and plotted on the standard curve 
using GraphPad prism version 6.0. Genome copy numbers were made relative to 
the mass of isolated tissue to generate a genome per gram tissue value.  
 
3.3.6. LAT expression 
Mice were sacrificed at indicated time points. The lower lip and TG were 
dissected and stored in RNAlater® RNA stabilization reagent (Thermo Fisher). 
RNA was isolated from tissue using PureLink™ RNA Mini procedure (Invitrogen) 
as previously described by the manufacturer. Complementary DNA (cDNA) was 
generated using the High-Capacity cDNA Reverse transcription procedure 
(Thermo Scientific) as previously described by the manufacturer. PCR was 
performed using primers against the major LAT species (forward: 
GGCGTCGGCGACATCC, reverse: CCCGAGTGTTCATCTCAGGC) (Nicoll et 
al., 2016) from the HSV-1 McKrae strain (accession: JX142173). 
3.3.7. Tissue digestion 
Mice were sacrificed 30 days after infection and tissue harvested. The lip 
and TG were immediately placed in DMEM on ice. The lip was digested using a 
cocktail of 3 mg/mL collagenase type 4 and 0.15 mg/mL DNAse 1 (Worthington 
Biochemical) at 37°C in the presence of 5% CO2. The digestive enzymes were 
quenched with FBS-containing media and the tissue pelleted. The tissue was 
resuspended in 1 mL of growth media. Remaining large pieces of tissue were 
dispersed using the plunger of a needle. Cells were pelleted and resuspended in 
1 mL of growth media.  
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The TG was digested using a Liberase TM (Roche Diagnostics) solution at 
a concentration of 2 units/mL for 1 hour in a 37°C water bath. The tissue was 
dispersed using a p200 pipette tip. The tissue was pelleted and resuspended in 1 
mL of growth media.  
3.3.8. Coculture of digested tissue and media sampling 
The resuspended digested tissue was plated evenly across Vero cells 
which were grown to 50% confluency. The digested tissue solution was allowed 
to settle on the Vero cells for 1 hour at 37°C in the presence of 5% CO2. FBS 
containing media was then added to the cultures and incubated for 10 days at 
37°C in the presence of 5% CO2. The media from the cocultures was sampled 
every day and stored at -80°C. Fresh complete growth media was replaced in the 
cultures after media sampling. At the end of the 10 days, the coculture 
monolayers were visualized and brightfield images were taken using an Olympus 
IX81 fluorescent microscope running CellSense Dimension version 1.13. The 
plates were then stained using Hematoxylin & Eosin dyes for plaque morphology 
staining. The collected media was used in standard plaque assay to determine 
when infectious HSV-1 virions could be detected in the media.  
3.3.9. Immunocytochemistry of isolated media samples 
Vero cells were grown to a confluency of 80% on autoclaved glass 
coverslips. Collected media from the reactivated tissue was plated over Vero 
cells and incubated at 37°C in the presence of 5% CO2. The cells were fixed 48 
hours later with 1% formaldehyde at 4°C and permeabilized with 0.05% Triton-X-
100. Polyclonal antibodies specific for HSV-1 were incubated overnight at 4°C to 
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detect HSV-1 antigen in the cultures. Goat anti-rabbit Alexa 555 (Molecular 
Probes®) conjugated secondary antibodies were used for detection of the 
primary antibodies. Cells were counterstained with DAPI (Invitrogen). Cells were 
visualized using an Olympus IX81 fluorescent microscope running CellSense 
Dimension version 1.13. 
3.3.10. Plaque morphology staining 
Vero cells were grown on autoclaved glass coverslips to a confluency of 
80%. Media sampled from cultured coculture wells was plated on Vero cells and 
incubated at 37°C in the presence of 5% CO2. The cells were then covered with 
Iscove's Modified Dulbecco's Medium (IMDM) + FBS (2%) in Methylcellulose 
(1.5%) and cultured for 4 days. When plaques were to be observed 
microscopically, the cells were fixed for 1 hour using 4% formaldehyde (10% 
neutral buffered formalin). The methylcellulose was removed and the cells 
washed with PBS + 0.05% Tween-20. The cells were permeabilized using 0.05% 
Triton-X-100 for 10 minutes and washed again. The nuclei were stained using 
Gills Hematoxylin III and the cell cytoplasm stained using Eosin Y. After washing 
and dehydrating, the cells were mounted on glass slides and images were 
obtained with an Olympus IX81 microscope running CellSens Dimension version 
1.13. Plaques from collected media were compared to plaques from stock HSV-1 
strains McKrae, 17+, and RE. 
3.3.11. Statistics 
All statistics were done using GraphPad prism version 6.0. 
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3.4. RESULTS 
3.4.1. Primary infection has resolved 30 days post-infection 
To determine if the lip scarification model can be used for studying HSV-1 
latency and reactivation, mice were infected and incubated for 30 days before 
analyzing them for presence of latent virus. After 30 days, the primary infection 
will have resolved, and the virus has time to establish latency in the TG. We 
observed no pathology in the lip by histology in mice 30 days post-infection. The 
upper lips from infected mice contained a normal epidermal layer which was 
indistinguishable from the control mice (Fig 3.1.A). This is in contrast to the lower 
lip in which active infection was occurring (Egan et al, 2016).  The lower lips from 
infected mice had increased inflammatory cells retained in the dermal layer. 
Immunohistochemistry was performed on the lip tissue sections and confirmed 
that no viral antigen could be identified. Antibodies specific for the T cell marker 
CD3 confirmed that a large number of the retained cells were T lymphocytes. 
Additional antibody labeling demonstrated that the majority of the cells were 
CD3+ CD4+ T cells which were found in the dermal layer of the lip. CD3+ CD8+ T 
cells could be could be found in the epidermal layer of the lip. We observed that 
CD3+, CD4+, and CD8+ T cells could be identified in hair follicles in the lip (Fig 
3.1.B).  These results are consistent with previous reports that virus specific T 
cells were retained in peripheral tissue where the original infection occurred 
(Mackay et al., 2012).  
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Figure 3.1. Mice do not exhibit pathology in the lip 30 days post-infection. 
Mice were inoculated with 6.0×105 PFU HSV-1 McKrae and allowed to recover 
for 30 days. The lower lip was processed for histological sectioning and staining.  
(A) Hematoxylin & Eosin staining of the lower lip. (B) Tissue sections were 
treated with antibodies specific for HSV-1 (green) and CD3, CD4, or CD8 (red) 
and counterstained with DAPI (blue). White arrowheads point to antibody positive 
cells which are located within hair follicles. One representative experiment is 
shown with n=3 mice.  
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Figure 3.1. 
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A hallmark of HSV-1 latency in animal systems is the infiltration into and 
retention of T lymphocytes within the TG. These cells begin infiltrating the TG 
during acute infection, then associate with and surround virus-infected neurons. 
After a contraction phase of the immune response, a reduced but still present 
population of virus-specific T cells is retained in the TG of the mouse (Fig. 3.2.A). 
Immunohistochemistry was performed using antibodies directed against CD3, 
CD4, and CD8 to confirm that these cells were retained in the TG 30 days post-
infection. Few T cells were still shown to be resident in the TG. Additional 
antibody labeling demonstrated that both CD4+ and CD8+ were still present in the 
TG during latency (Fig 3.2.B.). Confirmation that CD4+ and CD8+ T cells were 
identified in the TG was an important finding which provides additional evidence 
that infection resulting from topical administration of virus following lip 
scarification leads to retained lymphocytes in the TG similar to what has been 
reported in other routes of infection (Khanna et al., 2003).  
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Figure 3.2. CD4+ and CD8+ T cells are retained in the latently infected 
trigeminal ganglia. Mice were inoculated with 6.0×105 PFU HSV-1 McKrae and 
allowed to recover for 30 days. The TG was processed for histological sectioning 
and staining. (A) Hematoxylin and Eosin staining of the TG 30 days post-
infection. (B) Tissue sections were treated with antibodies against Neun (green) 
and CD3, CD4, or CD8 (red) and counterstained with DAPI (blue). White boxes 
indicate regions of interest which are shown in higher power panels on the right. 
One representative experiment with n=3 mice. 
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Figure 3.2. 
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3.4.2. Latent HSV-1 genomes are retained in the TG 
Latency from animal models is demonstrated by a lack of replicating virus 
present in the periphery and TG from infected animals. The lip and TG from mice 
sacrificed 30 days post-infection was analyzed for presence of replicating virus 
by standard plaque assay. We were unable to detect any replicating virus in the 
lip or TG from mice which were inoculated with HSV-1 McKrae (Fig. 3.3.A). 
We next determined if the lip or TG from infected mice retained HSV-1 
genomes. The lip and TG from mice sacrificed 30 days post-infection were 
harvested and genomic DNA isolated. PCR amplification of the thymidine kinase 
(TK) gene demonstrated that there were indeed HSV-1 genomes retained within 
the TG. We detected 1.3×103 HSV-1 genomes in the TG, which was consistent 
with our previous report of HSV-1 genomes present in the genomes at 15 days 
post-infection (Fig. 3.3.B).  In contrast, no viral genome copies were detected in 
the lip 30 days after infection. The RNA from mice sacrificed 30 days after 
infection was used to detect LAT expression in the TGs from mice. In this regard, 
LAT expression was detected in all TGs isolated from infected mice but no LAT 
could be detected in the lip samples (Fig. 3.3.C.).  
  
136 
 
Figure 3.3. The trigeminal ganglia contains viral genome copies 30 days 
post-infection. Mice were infected with 6.0×105 PFU HSV-1 McKrae. The mice 
were sacrificed 30 days post-infection, and the lip and TG were isolated.  Plaque 
assays were performed on cell-free homogenates from the lip and TG. PFU 
values were made relative to the mass of tissue analyzed (A). Viral genome 
copies present in the lip and TG were determined by qPCR . Genome copy 
values were made relative to the mass of the tissue analyzed (B).  Total RNA 
was isolated from the lip and TG and reverse transcribed. PCR was performed 
using primers specific for the major LAT species (C).  One representative 
experiment is shown with n=5 mice. 
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Figure 3.3.
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These results provide compelling evidence that latency can be established in 
mice inoculated via the lip scarification method. No pathology or viral antigen was 
shown to be present in the lip 30 days after infection. There are retained 
lymphocytes in the lip from infected mice where the original infection occurred, 
and these could play a role in limiting replication of future infections in that area. 
We demonstrated that the TG was infiltrated with CD3+ CD4+ and CD8+ T cells 
beginning during the acute infection and that these are retained through 30 days 
after infection. There was no infectious replicating virus present in the lip or TG at 
30 days post-infection. The number of genome copies present in the TG was 
consistent with levels present in the TG 15 days post-infection. We did not detect 
LAT expression in the lip tissue but LAT expression was consistently detected in 
the TGs. The bands observed were of an appropriate size with our predicted 
amplicon size of 85 bp.  
3.4.3. Ex vivo culture of TGs induces reactivation 
An important feature of any model of HSV-1 latency is the capability of the 
virus to reactivate. To study this process, TGs from mice sacrificed 30 days post-
infection with Vero cells were cocultured with permissive indicator cells. To this 
end, Liberase TM digestive cocktail was used to disperse surgically removed 
TGs into single cell suspensions. The digested TGs were apportioned onto 
monolayers of Vero cells, covered with growth media, and incubated for 10 days 
to allow infected cells to reactivate. The media from these cultures was sampled 
daily and used in standard plaque assays to determine when infectious virions 
had been produced.  
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We observed infectious virions present in the culture media from the TGs 
between 4 and 6 days after plating (Table 3.1). At the end of the 10 day 
incubation period, the monolayers displayed a clear cytopathic effect consistent 
with HSV-1 infection (Fig. 3.4.A) Compared to tissue from uninfected mice, the 
monolayers had multinucleated cell bodies which is evidence of cell fusion from 
neighboring infected cells. Plaque morphology staining in the primary cocultures 
revealed the fused multinucleated bodies and evidence of chromatin margination 
of infected cells (Fig. 3.4.B). Chromatin margination is a well-known viral 
inclusion body associated with HSV-1 infections and can be observed in HSV-1 
infected tissue and cell cultures (Leinweber et al., 2006). Similar chromatin 
margination was observed in our plaque morphology staining from stock HSV-1 
strains.  
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Table 3.1. Cultured lip and trigeminal ganglia tissue reactivate from latency 
Mouse Treatment Reactivation 
Day of TG 
reactivation 
Day of lip 
reactivation 
1 Vehicle No ND ND 
2 Vehicle No ND ND 
3 Vehicle No ND ND 
4 Vehicle No ND ND 
5 HSV-1 Yes 4 5 
6 HSV-1 Yes 4 7 
7 HSV-1 Yes 6 7 
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Figure 3.4. Cocultures of trigeminal ganglia from infected mice exhibit 
cytopathic effect.  The TGs from uninfected and infected mice 30 days after 
inoculation were enzymatically digested and plated on Vero cells. After 10 days 
in culture, the plates were fixed. (A) Brightfield imaging of cultures of Vero cells 
only (no tissue), cocultures with uninfected TGs (vehicle) and infected TGs 
(infected). White arrowhead points to an example of an area of cytopathic effect 
in the monolayer. (B) Plates were stained with Hematoxylin and Eosin dyes and 
imaged. Black arrowheads point to HSV-1 inclusion bodies.  
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Figure 3.4. 
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In order to confirm that the apparent cytopathic effect in the primary tissue 
monolayers was due to HSV-1, the sampled media was used to infect Vero cell 
monolayers and perform immunocytochemistry. Using polyclonal antibodies 
specific for HSV-1 antigen, HSV-1-positive cultures were detected from media 
derived from infected tissue coculture and HSV-1-negative cultures were 
obtained from media sampled from uninfected tissue coculture (Fig. 3.5). 
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Figure 3.5. Sampled media from trigeminal ganglia cocultures contain 
infectious HSV-1. The media from cocultured TGs from uninfected and infected 
mice was sampled daily for presence of infectious HSV-1. The sampled media 
was plated over monolayers of permissive Vero cells. The cells were fixed after 
48 hours and treated with antibodies specific for HSV-1 (red) and counterstained 
with DAPI (blue).  
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Figure 3.5. 
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3.4.4. Ex vivo cultivation of infected lips induces virus reactivation 
Previously we reported on the pathological and immunological events that 
occur during the acute phase of infection with HSV-1 using the lip scarification 
model. We observed that although there was a dramatic reduction in viral 
replication and genome copies between 8 and 15 days post-infection, there were 
still detectable genomes present in the lip. This result was interesting and led us 
to determine if this could be an example of established peripheral latency. 
Although we were unable to detect genome copies or LAT expression in the lip 
30 days post-infection, it was possible that the established latent infection was 
below the level of detection from these methodologies. To determine if it was 
possible that a peripheral latent infection has been established, enzymatically 
digested lip tissue was cocultured with Vero cells for 10 days. Even a very low 
amount of latently infected cells below the level of detection by PCR would be 
expected to reactivate and be detectable in the indicator Vero cells.  
The lips from mice infected with HSV-1 or treated with vehicle were 
surgically removed from sacrificed mice 30 days after infection. The lips were 
minced and digested using a cocktail of collagenase and DNAse1. The digested 
lips were dispersed and plated evenly on Vero cells and incubated for 10 days at 
37°C in the presence of 5% CO2. The media was sampled daily and used for 
plaque assay analysis for detection of produced infectious virions. At the end of 
10 days, the plates were fixed and imaged with brightfield microscopy before 
plaque morphological staining.  
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At the end of the 10 days, the monolayers exhibited cytopathic effect 
similar to those observed with the reactivated TG cultures. Clear areas of CPE 
could be distinguished from uninfected neighboring cells and were not observed 
in Vero cells with the digested lip from uninfected mice (Fig. 3.6.A). After staining 
with Hematoxylin and Eosin, the Vero cell monolayers displayed clear 
multinucleated cell bodies and chromatin margination (Fig. 3.6.B). 
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Figure 3.6. Cocultures of lip from infected mice exhibit cytopathic effect. 
The lips from uninfected or infected mice 30 days after inoculation were 
enzymatically digested and plated on Vero cells. After 10 days in culture, the 
plates were fixed. (A) Brightfield imaging of cultures of Vero cells, cocultures with 
uninfected lips and infected lips. White arrowhead points to areas of cytopathic 
effect in the monolayer. (B) Plates were stained with Hematoxylin and Eosin and 
imaged. White arrowheads point to hair shafts from mice present in the culture. 
Black arrowheads point to cytopathic effect and HSV-1 inclusion bodies.  
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Figure 3.6. 
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The sampled media from infected lip cultures was used for infecting new 
monolayers of Vero cells and performing immunocytochemistry. Using a 
polyclonal antibody specific for HSV-1 antigen, we confirmed that the plaques 
produced were from HSV-1 virions contained within the sampled media of 
reactivated explant lip cultures (Fig. 3.7). 
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Figure 3.7. Sampled media from trigeminal ganglia cocultures contain 
infectious HSV-1. The media from coculturing lips from uninfected and infected 
mice was sampled daily for presence of infectious HSV-1. The sampled media 
was plated over monolayers of Vero cells. The cells were fixed after 48 hours 
and treated with antibodies specific for HSV-1 and counterstained with DAPI.  
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Figure 3.7 
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3.4.5. Isolated virus produces plaques with consistent morphology to 
stock HSV-1 McKrae 
Finally to confirm that the reactivated HSV-1 was similar to the initial stock 
virus used to infect animals, a plaque morphology staining procedure was 
developed. This method, using standard histological Hematoxylin and Eosin 
dyes, was able to reveal great detail in differences in the plaques formed from 
different stock HSV-1 strains. Uninfected Vero cells exhibited plump cylindrical 
nuclei with prominent nucleoli. The stock HSV-1 McKrae strain revealed large 
areas of infected and dying cells that surrounded the cleared areas in the center 
of the plaques. The very center of the plaques contained cleared areas where 
cell death had already occurred. In addition, the center of the plaques contained 
large multinucleated cell bodies. The outer zone of infection contained many 
singular cells which were infected but still contained viral inclusion bodies such 
as chromatin margination.  The stock 17+ strain of HSV-1 (Brown et al., 1973) 
exhibited a similar large zone of infection surrounding the central zone of 
clearance of the plaque. However, the 17+ strain had numerous multinucleated 
cell bodies in the outer infection zone. The stock RE (Irvine et al., 1967) strain 
exhibited a very distinct plaque morphology with a very large zone of clearance in 
the center and the outer zone containing fused cells with 1-2 nuclei each and a 
prominent cell body border with neighboring fused cells (Fig. 3.8.A)  
The sampled media from the infected lip and TG cultures produced 
plaques consistent with the stock HSV-1 McKrae strain. There were large zones 
of infected cells surrounding a central zone of clearance which also contained 
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multinucleated cell bodies. The cells in the outer zone of infection were smaller 
and more round than the plump cylindrical cell bodies from uninfected cultures. 
Additionally, the cells in the outer zone of infection contained viral inclusion 
bodies including chromatin margination. The morphology of the plaques were 
most consistent with the morphology of the plaques produced by the stock HSV-
1 McKrae strain and not the other stock HSV-1 strains examined (Fig. 3.8.B and 
3.8.C).  
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Figure 3.8. HSV-1 from sampled media of lip and TG cultures has similar 
plaque morphology to the Mckrae strain. (A) Vero cells were infected with 
different clinical isolates of HSV-1 and stained with Hematoxylin and Eosin. (B) 
Media sampled from TG cultures of uninfected (left) and infected (right) mice was 
plated on Vero cells. The cells were then fixed and stained with Hematoxylin and 
Eosin. (C) Media sampled from lip cultures of uninfected (left) and infected (right) 
mice was plated on Vero cells. The cells were then fixed and stained with 
Hematoxylin and Eosin. White arrowheads point to prominent nucleoli in 
uninfected Vero cells. Black arrowheads point to chromatin margination in 
infected Vero cells.  
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Figure 3.8. 
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3.5. DISCUSSION 
We previously reported that the lip scarification model of infection was a 
physiologically relevant model for studying human HSV-1 infections in the 
orofacial tissue. Our model uses the HSV-1 McKrae as the infectious viral strain 
because it is particularly neurovirulent in animal models (Hill et al., 1987). We 
combined this neurovirulent model with the adult C57BL/6 mouse model because 
it is resistant to encephalitis caused by neurovirulent strains of HSV-1 (Kastrukoff 
et al., 2012). The inoculation route through the lip is particularly relevant to 
human infections but also minimizes the risk of encephalitis because of the 
greater distance that needs to be traveled to gain access to the TG and CNS. 
Taken together, this model has the potential to be of great value in studying 
HSV-1 infections in humans, establishment of viral latency, and HSV-1 
reactivation. Previously, we reported the pathological and immunological events 
that occur during the acute phases of infection. Here we report on the latent time 
points of infection following lip scarification and inoculation with HSV-1 McKrae.  
We confirmed that there was no pathology present in the lip consistent 
with the absence of replicating virus in mice which were productively infected 30 
days prior.  By 30 days after infection, the tissue architecture had returned to 
normal with a thin epidermis but increased cellularity. Immunohistochemistry 
assays revealed numerous CD3+, CD4+, and CD8+ T lymphocytes present in the 
lip (Fig 3.1). This is consistent with observations obtained with other models 
which demonstrate that memory T-cell populations reside in tissue sites where 
antigen was first encountered. These tissue resident memory T (TRM) cells were 
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retained in tissue locations where they can immediately respond to antigen 
previously seen and initiate memory responses.  TRM cells have been found in 
the skin of mice inoculated with HSV-1 through the flank skin (Mackay et al., 
2012), and are suspected to be in TG of mice inoculated with HSV-1 through the 
ocular route (Himmelein et al., 2011; Khanna et al., 2003).  
Animal models and post mortem tissue has consistently shown T cells to 
be retained in the TG after exposure to HSV-1 at a time postinfection at which no 
replicating HSV-1 virions can be detected. We used antibodies specific for CD3+, 
CD4+, and CD8+ T cells to confirm that these cells are retained in the TG of mice 
infected via lip scarification. As shown, we were able to detect them in tissue 
from mice 30 days after infection (Fig 3.2). The numbers of T cells present in the 
tissue 30 days after infection were low, but present in multiple sections and from 
all mice examined. It was possible that altering the dosage of virus would lead to 
a greater number of T cells retained in the TG. Because the C57BL/6 mice are 
resistant to encephalitis and the distal site of inoculation to the CNS, we can 
experiment with higher doses of virus to observe differences in immune 
responses.  
 A standard time point for examining latency in models was to look 28 days 
after infection. We believe that after 30 days, our mice have successfully 
established latency. We do not detect any replicating virus in cell-free 
homogenates in the lip or TG by plaque assay of freshly isolated tissue. PCR 
amplification of the TK gene demonstrates that viral genome copies are still 
maintained in the TG even though no replicating virus was detected.  PCR 
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amplification of the major LAT RNA species shows that the LAT gene was being 
expressed in the latently infected TGs (Fig 3.3). Lack of replicating virus, 
presence of HSV-1 genomes, and expression of the LAT gene are all hallmarks 
of a successful latent infection from in vivo models.  
 Surgical removal of latently infected tissue and coculture with indicator 
cells is a well known method used to induce reactivation from tissue. Instead of 
coculturing the whole tissue, the tissue was enzymatically digested to form a 
single cell suspension before plating. All of the TGs from mice which were 
infected reactivated after a delay between 4-6 days in culture (Table 3.1). This 
indicated that it was not due to the presence of undetectable infectious virus 
present in the tissue. The stress of sacrifice and surgical removal of tissue 
induced reactivation in latently infected cells. But the reactivation transcriptional 
program needs time before new infectious virions can be produced. The time 
delay between sacrifice and presence of infectious virions in a strong indicator 
that reactivation from latently infected cells has occurred. In order to confirm the 
transcriptional program has been initiated, a careful time course experiment must 
be done to detect presence of lytic transcripts to determine if a clear shift in 
patterns can be detected. The dispersal to single cell suspensions will allow the 
measurement of how many cells have been latently infected by infectious center 
assay.  
A surprising result was the presence of infectious virus in the media from 
the lip cultures. During tissue harvest, the lips were the first tissue removed. The 
time from animal sacrifice to removal of the lip is approximately 5 minutes. This 
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time window was too short for reactivation to be initiated in the TG and travel to 
the lip. This has indicated that HSV-1 found in lip cultures derived from a 
persistent low level infection in the lip or from reactivation from a peripheral latent 
site. We did not detect any infectious HSV-1 virions from freshly isolated lips by 
plaque assay of cell-free homogenates. These results suggest that the presence 
of infectious HSV-1 virions was likely due to reactivation from a latent state. HSV-
1 genomes were not detected in the lip by qPCR nor was LAT expression 
detected in the lip. It is possible if a latent infection is maintained in the lip, it was 
in such low levels that it was not detectable by these techniques. The media 
sampled from the lip cultures contained HSV-1 virions as confirmed by 
immunocytochemistry using antibodies specific for HSV-1 antigen. Additionally 
the plaque morphology staining confirmed that the HSV-1 was consistent with the 
input stock of HSV-1 McKrae strain. These results suggest that reactivation has 
occurred in lip cultures and the virus produced was HSV-1 and from the McKrae 
strain which was used to inoculate the mice.  
Peripheral latency has been a controversial idea in the field of HSV-1 
latency. Peripheral reactivation has been reported in the clinical setting of corneal 
transplantation (Higaki et al., 2015; Kaye et al., 1991). Some mouse studies have 
demonstrated that HSV-1 can be recovered from culturing mouse corneas 
(Abghari and Stulting, 1988). Additionally it was reported that the appearance of 
HSV-1 was delayed in the corneas compared to matched trigemina ganglia. 
However, there are similar mouse studies which fail to recover HSV-1 from 
latently infected mice (Easty et al., 1987). It appeared that the flexibility in mouse 
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strains along with different HSV-1 strains has led to an unexpected difficulty in 
comparing results from different mouse and HSV-1 strains. In order for this 
question to truly be addressed in mice, a singular mouse strain matched with a 
singular strain of HSV-1 should be used consistently in multiple experiments. We 
feel that the lip scarification inoculation method using C57BL/6 mice and HSV-1 
McKrae is a suitable model to study peripheral latency in the mouse lip.  
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4.1.ABSTRACT 
Herpes simplex virus type 1 (HSV-1) infections persist for the lifetime of 
the host. Current therapies are not curative as they do nothing to remove the 
latent genome of the virus or affect its ability to reactivate. CRISPR/Cas9 gene 
editing is a novel technique which targets the viral genome and has the potential 
to be uniquely curative. Guide RNAs (gRNAs) targeting HSV-1 immediate-early 
genes ICP0 and ICP27 were generated in an adeno-associated virus (AAV) 
vector system. We injected these AAV vectors into the lower lip of mice and 
evaluated expression of the gRNAs in the lip and TG. We observed maximal 
expression of gRNAs in the lip and TG 24 hours after injection. A high dose of 
AAV had greater expression of gRNAs in the lip compared to a low dose. 
However the low dose of AAV had greater expression in the TG compared to 
high dose. These studies demonstrate that CRISPR/Cas9 AAV vectors can be 
delivered locally and express gRNAs in peripheral tissue as well as the TG.  
 
  
168 
 
4.2. Introduction 
Herpes simplex virus type 1 (HSV-1) establishes a latent infection in 
humans which persists for the life time of the host. The acute infection is most 
often resolved without lasting pathology. But the virus remains in a latent state 
within the neurons innervating the initial site of infection, capable of reactivating 
periodically and causing recurrent disease. Gene editing technologies hold great 
promise for being a possible curative therapy for latent HSV-1 infections. 
Targeting HSV-1 genes in the latent episomal genome could prevent the virus 
from reactivating or even possibly eliminate the genome from infected neurons. 
Clustered regularly interspaced short palindromic repeat (CRISPR) Cas9 is a 
novel gene editing technology which uses guide RNAs to target DNA sequences 
for cleavage.  
During lytic replication of HSV-1, the viral genome exists as concatameric 
double-stranded DNA that is later cleaved to form singular units of the linear 
double-stranded DNA genome (Muylaert et al., 2011). In contrast to this, the 
latent HSV-1 genome is maintained as a circular episome that is bound by 
histones bearing repressive heterochromatin regions (Efstathiou et al., 1986b; 
Rock and Fraser, 1983). Viral transcription during latency is repressed and the 
only viral gene found to be abundantly expressed is the latency-associated 
transcript (LAT) (Javier et al., 1988; Wagner et al., 1988; Wagner and Bloom, 
1997). There is leaky transcription of other viral lytic genes, but they do not 
appear to lead to translation of viral proteins in appreciable numbers and 
amounts. When reactivation is initiated in response to specific triggers, viral lytic 
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gene transcription initiates and the virus undergoes productive replication in the 
neuron. Newly formed HSV-1 virions (or potentially capsids) traffic down the axon 
of the innervating sensory neuron and are released into the periphery where the 
axonal termini are located. The released virions undergo productive infection in 
the peripheral site with associated pathology of reactivation events.  
Current antiviral therapies available consist of nucleoside analogs (Villa et 
al., 2016). Acyclovir and it’s derivatives are preferentially phosphorylated by the 
viral-encoded thymidine kinase and the triphosphorylated compounds are 
preferentially incorporated into the elongating HSV-1 genome as a result of the 
activity of the HSV-1-encoded DNA polymerase (Birkmann and Zimmermann, 
2016). The triphosphorylated nucleotide analogs lack the requisite ribose sugar 
and hydroxyl group for addition of new nucleotides to the analog and therefore 
halt elongation of the viral genome after their incorporation and the viral 
replication process is subsequently halted. Although these therapeutics have 
proven to be highly effective in treating primary and recurrent infections, they 
only act on actively replicating virus. These therapeutics have no activity on the 
latent HSV-1 genome and thus do not constitute a curative therapy. In order to 
prevent future reactivations, a person must always be on a course of chain 
termination therapy.  A potential curative therapy must have the ability to target 
the latent HSV-1 genome for irreversible inactivation or complete removal of the 
latent genome.  
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CRISPR-Cas9 gene-editing is a novel technique which has the potential 
for such targeting.  CRISPR/Cas9 was originally discovered as an ancient 
antiviral response in bacteria (Barrangou et al., 2007). The Cas9 protein acts as 
a nuclease to introduce cleavages in DNA sequences (Ehrlich et al., 2005; 
Makarova et al., 2006; Marraffini and Sontheimer, 2008). The Cas9 protein is 
guided to target DNA by guide RNAs (gRNAs) which hybridize to the targeted 
DNA sequence (Jinek et al., 2012). The target DNA sequences must be 
immediately followed by a Protospacer adjacent motif (PAM) sequence for the 
Cas9 protein to cleave the target DNA. The promise of the CRISPR/Cas9 
technique is that as long as a DNA sequence contains PAM sequences, then 
gRNAs can be designed which will direct the Cas9 protein to cut at that site. This 
technique is already being explored for gene therapy use in humans for 
correcting heritable disorders arising by single nucleotide polymorphisms (SNPs) 
(Chang et al., 2015).  
A delivery of Cas9 protein and gRNAs to cells harboring latent HSV-1 
genomes could lead to efficient targeting of the viral genome for editing. 
Targeting of genes required for replication could inhibit the virus from being able 
to reactivate from latency. Recently, investigators have begun to experiment with 
gRNAs targeting HSV-1 genes using in vitro experiment model systems. Stable 
Vero cell lines which express gRNAs targeting a variety of HSV-1 genes have 
shown efficacy in limiting HSV-1 replication. Most gRNAs targeting HSV-1 genes 
were ineffective at limiting replication 3 days post-infection, but gRNAs targeting 
the primase-helicase complex remained inhibitory (van Diemen et al., 2016).  
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Plasmids encoding Cas9 and gRNAs targeting the HSV-1 immediate- early 
genes ICP0, ICP4, and ICP27 have been generated and tested in vitro. These 
experiments demonstrated that HSV-1 infection was limited when cells were 
treated with gRNAs. Additionally, it was found that the HSV-1 genome had 
insertions/deletions caused by Cas9 nuclease activity in targeted sequences.  
Finally, the designed gRNAs were found to have minimal off-target effects 
(Roehm et al., 2016).  
In this chapter, we treated mice with AAVs encoding gRNAs which target 
the HSV-1 immediate early genes ICP0 and ICP27. We wanted to evaluate if 
AAV delivered gRNAs are expressed in the lip and the TG. We used a local 
delivery of AAVs by injecting directly into the lower lip of anesthetized animals. 
We found that the gRNAs are maximally expressed 24 hours after injection. An 
important finding was that AAVs delivered to the lower lip were capable of 
making it to and express the gRNAs in the TG.  
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4.3. MATERIALS AND METHODS 
4.3.1. Mice  
Wild-type C57BL/6 adult (procured at 12 weeks of age) male mice were 
purchased from Jackson Laboratories. All animal experiments adhered to 
procedures and guidelines approved by the Institutional Animal Care and Use 
Committee (IACUC) of Drexel University. Mice were anesthetized with Avertin 
and AAV vectors were injected directly into the lower lip in a volume of 10 µl.  
4.3.2. Design of CRISPR gRNAs targeting HSV-1 genes 
Preparation of CRISPR gRNAs targeting the second exon of ICP0 was 
performed as previously described (Roehm et al., 2016). Briefly, the sequence of 
HSV-1 ICP0 was obtained (NC_0018061) and gRNA targets were designed 
using available online tools by Kamel Khalili at Temple University. gRNAs 
targeting the HSV-1 ICP4 and ICP27 genes were also generated from available 
databases and online tools. The gRNAs were cloned into pX260 plasmid vectors 
with a Cas9 gene. Plasmid vectors encoding Cas9 and the gRNA targeting the 
appropriate immediate-early gene (ICP0, ICP4, or ICP27) were grown up using 
DH5 alpha bacteria and the plasmid isolated using the plasmid Maxi procedure 
(Qiagen) as previously described by the manufacturer. The DNA concentration 
was obtained by spectrophotometry.  
4.3.3. Mouse treatment with AAV gRNA vectors  
AAV vectors encoding Cas9 and gRNAs targeting ICP0 or ICP27 were kindly 
provided from Kamel Khalili at Temple University. A cocktail of AAV encoding 
gRNAs targeting ICP0 and ICP27 at a concentration of 4.3×1010 PFUs  or 
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2.×1010 PFUs respectively in a final volume of 10 µl (1X) was injected into the 
lower lip of anesthetized mice. We also used a cocktail of AAVs encoding ICP0 
and ICP27 gRNAs at a concentration of 21.5×1011 and 1.4×1011 PFUs 
respectively in a volume of 10 µl (5X).   Mice were allowed to recover and then 3 
mice were sacrificed at indicated times. The lower lips and TGs were harvested 
and frozen in Dulbeccos Modified Eagles Medium (DMEM).  
4.3.4. Evaluation of gRNA expression in tissue 
The RNA from mouse tissue was isolated using TRIzol® Reagent. The tissues 
were homogenized using a Bullet Blender™ with zirconium oxide beads. The 
homogenate was incubated with TRIzol® Reagent and the RNA isolated using a 
pheno chloroform procedure per manufacturer’s protocol. 
4.3.5.Statistics 
Data were graphed using GraphPad Prism version 6.0.  
 
4.4. RESULTS 
4.4.1 ICP0 gRNAs are maximally expressed in the lip 24 hours after 
injection 
CRISPR/Cas9 mediated gene therapy has a great potential to be a therapeutic 
which can act on latent HSV-1 genomes. There are numerous vectors which can 
serve to deliver DNA sequences encoding Cas9 and targeted gRNAs to cells in 
vivo. AAV vectors are already being used for gene therapy in humans and have 
been used to delivery CRISPR/Cas9 sequences in mice. We employed AAV 
vectors encoding Cas9 and gRNAs which target the HSV-1 immediate early 
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genes ICP0 and ICP27. We delivered a cocktail of AAVs targeting both HSV-1 
genes through direct injection into the lower lip. We tested two different doses of 
the AAVs (1X) and (5X) as described in the methods. Mice were sacrificed at 
indicated time points and the lip and TG were harvested. We evaluated the lip 
and TG from treated mice for expression of gRNAs targeting HSV-1 genes.  
 We found that AAV delivered gRNAs targeting ICP0 were maximally 
expressed 24 hours after injection. The highest expression was seen in mice 
treated with the 5X dose of the AAV vectors. After 24 hours, the expression 
levels of the gRNAs decreased through 3 days post-injection. The 1X dose did 
not have the same level of decrease, but was 2 logs reduced in relative 
expression level compared to the 5X dose (Fig 4.1.). 
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Figure 4.1. AAV delivered gRNAs targeting ICP0 are maximally expressed 
24 hours post-injection.  AAVs encoding gRNAs which target ICP0 were 
directly injected into the lower lip of mice. The mice were allowed to recover and 
at indicated time points, were sacrificed. The lower lip was harvested and 
expression levels for the gRNAs was determined. Expression levels are relative 
to the house keeping gene beta actin.  
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Figure 4.1. 
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4.4.2. Expression of ICP27 gRNAs in the lip is highest 24 hours after 
injection.  
 We next evaluated if the AAV delivered gRNAs which target ICP27 are 
expressed in the lip after injection. We found that these gRNAs also have the 
highest relative expression in the lip 24 hours after injection. The expression 
decreased as the length of time after injection increased. Similar to the ICP0 
gRNAs, the 5X dose of AAVs had a much greater relative expression of gRNAs 
compared to the 1X dose of gRNAs in the lip. One interesting result is that the 1X 
dose of AAVs seemed to increase in expression at later time points, but the level 
of expression of the 1X gRNAs did not approach the expression level seen with 
the 5X dose during the time period examined (Fig 4.2).  
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Figure 4.2. Expression of ICP27 gRNAs in the lip is highest 24 hours after 
injection. AAVs encoding gRNAs which target ICP0 were directly injected into 
the lower lip of mice. The mice were allowed to recover and at indicated time 
points, were sacrificed. The lower lip was harvested and expression levels for the 
gRNAs were determined. Expression levels are relative to the house keeping 
gene beta actin.  
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Figure 4.2. 
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4.4.3. ICP0 gRNA expression in the TG is highest 24 hours after injection 
An important consideration when evaluating AAV delivered CRISPR/Cas9 
therapeutics is tissue specific expression. Because CRISP/Cas9 gene editing 
can potentially be a therapeutic which acts on the latent HSV-1 genome, we 
need to evaluate if the AAV delivered vectors reach the TG. Previous reports 
have demonstrated that intraperitoneal injected AAV vectors are capable of 
reaching the TG. However we sought to examine if locally delivered AAVs 
injected into the lower lip were able to express gRNAs in the TG.  
The TGs from mice treated with either the 1X or 5X dose of the AAV 
cocktail were evaluated for expression of gRNAs. We found that like the lip, 
maximal expression was observed in the TG 24 hours after injection. However a 
surprising finding was that the 1X dose of AAVs had greater expression in the 
TGs that the 5X dose. This is contrast with the data from the lip which 
demonstrated the opposite. We observed that expression In the TG began to 
decrease at time points tested after 24 hours (Fig 4.3).  
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Figure 4.3. ICP0 gRNA expression in the TG is highest 24 hours after 
injection. AAVs encoding gRNAs which target ICP0 were directly injected into 
the lower lip of mice. The mice were allowed to recover and at indicated time 
points, were sacrificed. The TG was harvested and expression levels for the 
gRNAs were determined. Expression levels are relative to the house keeping 
gene beta actin.  
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Figure 4.3. 
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4.4.4. ICP27 gRNAs are maximally expressed in the TGs 24 hours after 
injection.  The TGs from mice treated with either the 1X or 5X dose of the AAV 
cocktail were evaluated for expression of gRNAs. We found that like the lip, 
maximal expression was observed in the TG 24 hours after injection. An 
interesting finding is that the relative expression of the ICP27 gRNAs were 
comparable between the 1X and 5X doses. The 1X dose had a slightly higher 
relative expression, but the difference was much smaller than seen with the ICP0 
gRNAs.  As we have seen with the other tissues analyzed, relative expression 
decreased at time points analyzed after 24 hours (Fig 4.4).  
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Figure 4.4. ICP27 gRNAs are maximally expressed in the TGs 24 hours after 
injection.  AAVs encoding gRNAs which target ICP27 were directly injected into 
the lower lip of mice. The mice were allowed to recover and at indicated time 
points, were sacrificed. The TG was harvested and expression levels for the 
gRNAs were determined. Expression levels are relative to the house keeping 
gene beta actin.  
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Figure 4.4. 
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4.5. DISCUSSION 
The CRISPR/Cas9 gene editing technique has the potential to be a 
curative therapeutic. Current antiviral therapies can only act on actively 
replicating virus. This means that current therapies cannot target the latent HSV-
1 genome maintained in infected neurons. People who suffer reactivations can 
begin taking therapies when prodrome is felt and the recurrent disease limited. 
However the therapeutics cannot limit the potential for new reactivations. 
CRISPR/Cas9 is a gene editing which has the ability to act on the latent HSV-1 
genome in infected neurons. Designed gRNAs will bring the Cas9 endonuclease 
to targeted sequences and double strand breaks introduced. The DNA repair 
mechanism of the cell will introduce mutations into the genomic sequence.  
Delivery of CRISPR/Cas9 in vivo will be an important step towards making 
it into a therapeutic. Viral vectors including AAV vectors are currently being used 
in the clinic for gene therapy applications. We investigated the potential for AAV 
vectors to delivery CRISPR/Cas9 gRNAs to tissues of interest and express the 
desired genes. We injected AAVs directly into the lower lip of mice and evaluated 
if gRNAs are expressed in the lip and importantly in the TG. Delivery and 
expression in the TG will be necessary for CRISPR/Cas9 to act on the latent 
HSV-1 genome and be an effective curative therapy.  
Mice were treated with AAV vectors encoding gRNAs targeting the HSV-1 
immediate early genes ICP0 and ICP27. Mice were sacrificed at indicated time 
points and the tissue evaluated for expression of the gRNAs. We tested 2 
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different doses of AAV vectors and compared the expression of gRNAs from the 
different doses.  
 We observed that the ICP0 gRNAs had highest expression 24 hours after 
injection in the lip and TG. The expression levels declined at time points after 24 
hours. We found that the 5X dose had the highest expression of gRNA in the lip. 
However in the TG, the highest expression was seen with the 1X dose. The 
ICP27 gRNA similarly had the highest expression 24 hours after injection in the 
lip and TG. The 5X dose of the ICP27 gRNA had the highest expression in the lip 
24 hours after injection. Finally the 1X dose of the ICP27 had the highest 
expression in the TG 24 hours after injection.  
 The majority of the AAV vectors had maximal expression in the lip and TG 
24 hours after injection. This indicates that timing of administration of the AAVs 
will be critical when testing CRISPR/Cas9 AAV vectors in vivo. Treatment with 
AAV vectors too early before infection will lead to decreasing expression of 
gRNAs before the Cas9 can encounter viral genomes. Additionally if the AAV 
vectors are delivered too late, then the virus has the potential to replicate to a 
level that the CRISPR/Cas9 won’t have a significant effect. These studies will 
inform future experiments in regards to the timing of AAV administration and viral 
infection.  
Another interesting result was the difference in expression observed 
between the different doses of AAV administered. We consistently observed that 
the 5X dose had the highest expression in the lip whereas the 1X dose had 
highest expression in the TG. It is possible that in the large tissue area of the lip, 
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there’s a large number of susceptible cells which can be transduced by the AAV 
vectors. Additionally it is important to consider that AAV is transducing cells by 
viral infection with some related pathology and immune responses. It is possible 
that the large amount of AAV vectors delivered in the 5X dose is causing damage 
in the lip and possibly the innervating axons and limiting delivery of AAV vectors 
to the TG. The smaller amount of viruses delivered in the 1X dose has less 
damage in the lip and possibly innervating neurons which can allow for a greater 
number of AAV vectors being delivered to the TG.  
There are still important questions that need to be addressed in future 
experiments. The expression and production of the Cas9 protein needs to 
evaluated in the lip and TG. Additionally it will be important to identify the cells 
which are being transduced in the TG. The studies in this paper only show that 
the gRNAs are bring expressed, they do not indicate that they are being 
expressed in neurons which have the potential to harbor latent HSV-1 genomes.  
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 5.1. Overall summary 
The studies presented in this dissertation examined the lip 
scarification model of HSV-1 infection. The lip scarification model closely 
resembles the natural inoculation site for the majority of new HSV-1 
infections in humans. Chapter II described studies of the events that occur 
during acute primary infection using the lip scarification model. Chapter III 
described studies to explore the potential for the lip scarification model to 
be used to study latency and reactivation.  Finally, in Chapter IV studies 
were performed to develop a new therapeutic tool for treating acute HSV-1 
infections using gene editing technology. This chapter summarizes our 
observations, discusses translational implications, and addresses future 
studies which should be performed.  
 
5.2. The course of primary infection using the lip scarification model 
Infected mice develop clinical lesions 
 
Using the lip scarification model of infection, we examined mice at 
various time points for apparent clinical lesions at the site of inoculation. 
The vehicle treated animals showed no pathology associated with the 
scarification procedure. Additionally in virus treated animals, no pathology 
could be observed at the earliest time points observed. However large 
erythematous lesions appeared on the lower lip beginning 5 days post-
infection. These lesions appeared to be vesicular and a crust could be 
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observed. Virus treated animals presented healing lesions on the lower lip 
8 days post-infection. No clinical lesions could be identified on mice 15 
days post-infection.  
We processed the lower lips and trigeminal ganglia (TG) from mice 
sacrificed at selected time points after infection. Staining of tissue sections 
with Hematoxylin and Eosin (H&E) revealed a degraded and compromised 
epidermal layer that was then later covered with a proteinaceous crust and 
eventually restored and healed by 15 days post-infection. The degraded 
tissue contained viral inclusion bodies consistent with HSV-1 infections in 
humans. The healed dermal layer contained an abundance of retained 
leukocytes.  
Immunohistochemistry revealed that HSV-1 antigen is initially found 
on the surface of the lip before being found abundantly in hair follicles of 
the dermal layer. HSV-1 antigen is not detectable in the lower lip 8 days 
after infection. CD45+ leukocytes rapidly infiltrate the lip and associate with 
areas of tissue containing HSV-1 antigen. The CD45+ leukocyte infiltration 
begins to contract by 8 days post-infection, but a large number are still 
present 15 days post-infection.  
We showed by plaque assay that the peak of cell-free virus could 
be found in the lip between 2 and 5 days post-infection. No cell-free virus 
could be detected in the lip 8 days after infection. The peak of cell-free 
virus in the TG occurred at 5 days post-infection. This indicated a time 
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delay needed for the virus to travel from the site of inoculation to the TG. 
No cell-free virus could be detected in the TG 8 days after infection.  
A genome copy assay was performed to determine the levels of 
HSV-1 genomes present in lip and TG at selected times. Consistent with 
the plaque assays, the highest viral genome copy number occurred in the 
lip at 5 days post-infection. Peak levels of genome copies in the TG were 
obtained 5 days post-infection. However, a steady state level of genomes 
was established in the TG which persisted through 15 days post-infection 
These data demonstrate the ability of the lip scarification technique 
to model infection of the orofacial epithelial tissue. We were able to detect 
clinical lesions which were similar to lesions which appear on humans who 
are suffering reactivations. Similar to what is observed in patients, clinical 
lesions on mouse lips correlated with histopathological evidence of 
infection. Specifically, we observed well characterized HSV-1 viral 
inclusion bodies and a large proteinaceous crust covering areas of 
epidermal degradation. Treatment of lip sections with antibodies specific 
for HSV-1 antigen revealed that the virus accumulates to high levels in the 
hair follicles. This is an interesting finding as it demonstrates that the lip 
model can also be used to study the disease herpes folliculitis (Böer et al., 
2006).  
The time frame of acute infection by exhibited clinical lesions were 
consistent with that of human reactivations There are no prospective 
studies of human HSV-1 infections with associated histopathology, so the 
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process of lesion formation and resolution is unknown. A clinical study 
comparing achieved samples of human histopathology from HSV-1 
infections to those of the mouse lip scarification model will confirm the 
accuracy of disease modeled. The model can then be used to study the 
formation and resolution of HSV-1 lesions in the orofacial epithelia.  
After utilizing the model to characterize the process of lesion 
formation and resolution, the model can then be used to address more 
interesting questions. Current and future therapeutics can be analyzed by 
their effect on the histopathology of HSV-1 infections in the lip. New 
therapeutics will be measured not only in the time course of clinical lesions 
but also by reduction of tissue damage of the lip.  
Another interesting question which has not been addressed by 
human clinical studies or other animal models is the nature of lesions 
caused by reactivations from latency. The data presented in this 
dissertation can inform us about the process of lesion formation from virus 
which is topically administered. The data in chapter 3 confirmed that a 
latent HSV-1 infection is established and is capable of reactivating. 
Inducing reactivation in vivo can allow us to determine the process of 
lesion formation and resolution from the endogenous latent HSV-1 
infection. We can evaluate if changing the originating source of virus input 
affects the location and severity of pathology present in the tissue.  
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Leukocytes infiltrate the trigeminal ganglia 
TG sections from mice sacrificed at selected times were stained with 
H&E. We did not observe any specific pathology in neurons from infected 
animals. Cellular infiltration was observed beginning 5 days post-infection. We 
saw that infiltrating cells associated with and surrounded neuronal cell bodies at 
8 and 15 days post-infection. Immunohistochemistry confirmed the infiltrating 
cells were CD45+ leukocytes responding to HSV-1 infection of the TG. The 
CD45+ cells surrounded neurons in the TG and were retained through 15 days 
post-infection. We also determined that CD3+, CD4+, and CD8+ T cells can be 
found in the TG 15 days post-infection. 
These data are important for demonstrating the immune response to 
HSV-1 infection in the lip involves TG infiltration with leukocytes. There is a large 
body of evidence which demonstrates that CD4+ and CD8+-T cells can be found 
in the TG (Khanna et al., 2003; Liu et al., 1996). Mouse in vivo studies further 
confirmed that CD8+ T-cells play a role in maintaining the virus in a latent state 
(St Leger and Hendricks, 2011). Disruption of CD8+ T-cell function or the pool of 
CD8+ T-cells accelerated reactivation from latency  (Cherpes et al., 2008; 
Freeman et al., 2008). This can be corroborated in humans because stress 
inhibits CD8+ T-cell function and people suffering high levels of stress 
consistently have higher rates of reactivation (Glaser and Glaser, 1998).  
Further studies will allow us to define the immune cells which comprise 
this acute phase TG infiltration. We can establish a time course of infiltration from 
different populations of immune cells. We can further establish the contraction of 
immune response and determine what specific cell populations are likely to 
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remain retained in the TG. These studies will be useful for studies to determine 
the nature of Tissue Resident Memory T-cells (TRM).  
5.3. Latency and reactivation from mice inoculated via lip scarification 
We processed lip and TG tissue from mice sacrificed 30 days post-
infection and stained with H&E. There were no signs of pathology present in 
the lip 30 days post-infection. The epidermal layer was intact and not 
enlarged. Immune cells could be found retained in the lip 30 days after 
infection, and immunohistochemistry revealed them to be CD3+, CD4+, and 
CD8+ T-cells. Cells bearing these markers could be found in hair follicles 
where a large accumulation of HSV-1 antigen was observed during acute 
infection. Immunohistochemistry performed on TG sections revealed that 
CD3+, CD4+, and CD8+ T-cells could be found in the TG. The T cells were 
found closely associated with neurons.  
This is an important result that correlates the immune response in the lip 
model to responses seen in other mouse models and human post-mortem 
samples (Held et al., 2012; Khanna et al., 2003; van Velzen et al., 2013). The 
role of T-cells in maintaining the virus in the latent state has not been firmly 
established. Some investigators have suggested that CD8+ T-cells in the TG 
are not involved in maintaining the virus in the latent state (Held et al., 2011). 
Other investigators have demonstrated that inhibition of T cells from latently 
infected tissue leads to accelerated reactivation from latency (Liu et al., 
2000).  
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The presence of CD4+ and CD8+ T-cells in the lip and TG suggests that 
the lip scarification model can be used to study the formation and role of 
immune cell populations maintained in tissue. We hypothesize that the CD8+ 
T-cells in the lip and TG belong to the TRM class of memory T-cells. In 
contrast to CD8+ effector memory T cells, these cells will remain retained in 
the tissue where antigen was first encountered. The proximity to these cells 
ensures that memory immune cells will be available to rapidly respond to 
reexposure to antigen in tissue.  
TRM cells have been identified in numerous tissues including the brain 
(Casey et al., 2012), intestines (Masopust et al., 2006), lungs  , liver (Tse et 
al., 2013) and recently in the spleen and lymph nodes (Schenkel et al., 2014). 
TRM cells arising from HSV infections have been confirmed in the skin 
(Mackay et al., 2013), dorsal root ganglia (Gebhardt et al., 2009) and female 
genital tract (Iijima and Iwasaki, 2014). A distinctive tissue pattern was seen 
in TRM cells of the skin in mice following HSV-1 challenge. CD4+ TRM cells 
were found localized in the dermis  while CD8+ TRM cells were found in the 
epidermal layer (Mackay et al., 2013). Both CD4+ and CD8+ TRM cells could 
be found in hair follicles. The results of our immunohistochemistry 
experiments in the lower lips of mice following HSV-1 inoculation closely 
match this tissue localization. The CD8+ T-cells in the lip were found in either 
the epidermis of hair follicles. The CD4+ T-cells in the lip were found in the 
dermal layer or in the hair follicle.  
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The canonical markers used for identifying TRM cells are CD69 and 
CD103. CD69 is commonly known to be a recent activation marker in T cells, 
but also serves to downregulate expression of genes which help cells migrate 
out of tissues  (Skon et al., 2013). CD103 is an integrin receptor which binds 
to e-cadherin. It is hypothesized that this interaction helps cells to remain in 
the tissue where antigen was first encountered. Flow cytometry is the best 
method for determining the variety of markers present on cells in tissue. To 
confirm TRM cells are retained in the lip and TG, we would need to 
demonstrate CD69 and CD103 expression. TRM cells have decreased 
expression of the chemokine receptor CCR7 and sphingosine 1 phosphate 
receptor (S1PR1) which receives signals that induce tissue exit and 
circulation. Additionally cell tracing experiments should be done to confirm 
that these cells are not being seeded from the circulation. TRM cells are 
believed to be homeostatically quiescent meaning that they are not actively 
replicating to replenish their population, instead consisting of a long lived 
population. To confirm this we would analyze cells for the presence of the 
replication marker Ki-67 in cells isolated from the lip and TG.  
The timing of TRM cell generation is an interesting question which can be 
addressed using this model. One theory is that TRM cells are generated from 
differentiation of memory T cells which are already present in the peripheral 
tissue site where antigen is encountered. Preliminary data from our lab 
demonstrate CD69+ CD103+ CD8+ T-cells in the TG 5 days post-infection 
(unpublished data). These results could point to an alternative hypothesis that 
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TRM cells are seeded in the peripheral sites during the acute phase and are 
retained following contraction of the immune response. TRM cells have been 
found in the spleen and lymph node of mice. These cells could be a source of 
TRM cells seeding into the peripheral sites. The lip scarification model can be 
used to explore these alternative hypotheses.  
 
The TGs from latently infected mice harbor HSV-1 genomes 
We isolated DNA and RNA from the lips and TGs of mice sacrificed 30 
days post-infection. We did not detect any HSV-1 genomes or LAT expression in 
the lips from latently infected mice. This was not surprising in the context of our 
current understanding of peripheral HSV-1 infections. However, it did not 
completely eliminate the possibility that latent HSV-1 genomes existed in the lip 
from mice. It is possible that the number of latent genomes present within the lip 
was below the level of detection using these techniques. 
Trigeminal ganglia from these mice had no infectious cell-free virus, but 
had HSV-1 genomes present in levels similar to what was observed 15 days 
post-infection. We were also able to detect LAT expression in these tissues, 
providing future evidence that latency has been established in these mice 30 
days after infection.  
Cultured TGs from infected mice reactivate from latency 
We cocultured TGs from mice sacrificed 30 days post-infection with Vero 
indicator cells. During the 10 day culture period, the Vero cell monolayer began 
displaying cytopathic effect (CPE) consistent with in vitro HSV-1 infections. H&E 
201 
 
staining of the Vero cell monolayer demonstrated viral inclusion bodies 
consistent with HSV-1 infection. Media sampled 4-6 days after the initial 
coculture plating produced plaques on new Vero monolayers which indicated 
reactivation had occurred in the TGs. The plaques were positive for HSV-1 
antigen and had morphology consistent with stock HSV-1 McKrae. These results 
provide evidence that TGs from infected mice harbor latent HSV-1 that is 
reactivating. The plaque morphology indicates that the virus produced from these 
cultures is the same as the strain of HSV-1 used to inoculate mice.  
Cultured lips from infected mice reactivate from latency 
We cocultured lip tissue from mice sacrificed 30 days post-infection with 
Vero indicator cells. As with the TG coculture, during the 10 day culture period, 
the Vero cell monolayer began displaying CPE consistent with HSV-1 infections 
in vitro. H&E staining of the Vero cell monolayer demonstrated viral inclusion 
bodies consistent with HSV-1 infections. Media samples from 5-7 days after 
plating produced plaques, indicating reactivation occurred. The plaques were 
positive for HSV-1 antigen and had morphology consistent with stock HSV-1 
McKrae. These results provide evidence that lips from infected mice harbor latent 
HSV-1 that is reactivating. The plaque morphology indicated that the virus 
produced from these cultures was the same as the strain of HSV-1 used to 
inoculate mice.  
There are still many more questions which need to be addressed to 
thoroughly characterize latency and reactivation in the lip scarification model of 
infection. We used only a single dose infection and demonstrated that we could 
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detect latent HSV-1 genomes in the TG, LAT expression, and a capability for 
latent genomes to reactivate. Additionally we were able to detect reactivation in 
lips that were cocultured with Vero cells after sacrifice. However we were not 
able to detect latent HSV-1 genomes or LAT expression in nucleic acids isolated 
from the lips of mice infected. It is possible that any latent HSV-1 genomes 
present in the lip are below a level that we can detect. Future experiments 
exploring higher doses of input virus can help us determine an optimal 
concentration for infection. Higher input dose of virus is correlated with an 
increased level of latent HSV-1 genomes in the TG. An ideal dose would allow 
mice to recover from acute infection without any CNS disease, no persistent 
replication in the tissue, and an increased number of HSV-1 genomes in the lip 
and TG. If we are still not able to detect latent HSV-1 genomes in the lip, we can 
use a nested PCR approach which has a higher sensitivity for low levels of target 
DNA.  
A larger level of latent HSV-1 genomes are also correlated with an 
increased frequency of reactivation. This will allow us to conduct more 
quantitative experiments into the nature of latency and reactivation in the lip and 
TG. Infectious center assays can be used to measure the number of infected 
cells in the lip and TG which harbor latent HSV-1 genomes. We can localize the 
latent HSV-1 genomes in the lip and TG tissue sections using in situ 
hybridization. This is an important experiment which can reveal what cells are 
harboring latent HSV-1 genomes in the lip. Culture experiments on recently 
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dissected lips and subsequent histological processing can also reveal the 
process of reactivation in the lip.  
With these data demonstrating retention of T cells in tissue and the ability 
of explanted tissue to reactivate, we can begin to explore the role that immune 
cells play in maintaining the virus in the latent state. An important first experiment 
will be to demonstrate that T cells associate with cells harboring latent HSV-1 
genomes in the lip and TG. Explanted and digested tissue can be treated with 
antibodies that will inhibit the activity of CD4+ and CD8+ T-cells in culture. The 
rate and intensity of reactivation will inform reveal the effect these cells are 
having on maintaining latency. In vivo experiments which deplete specific T cell 
populations can also be used to explore the effect of immune cells on 
maintenance of latency.  
Finally we will explore in vivo reactivation studies in mice inoculated 
through the lip scarification model of infection. Being able to induce in vivo 
reactivation is important for the model to be appropriate for an animal model to 
study latency and reactivation. Common triggers of in vivo reactivation in mouse 
models include restraint stress, hormone injections, and variable temperature 
stressors. In addition to these triggers, we will explore triggers of reactivation that 
act on a local level. A second treatment of lip scarification might be enough to 
trigger a reactivation event in the lip. Additional local triggers can be ultraviolet 
(UV) light inactivated viruses that can induce a memory immune response and 
capsaicin.  
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5.4. Delivery of CRISPR/Cas9 gRNAs targeting HSV-1 immediate early 
genes using AAV vectors. 
 CRISPR/Cas9 gene editing has the potential to lead to a curative therapy 
for latent HSV-1 infections. We tested delivery of CRISPR/Cas9 gRNAs via 
adeno-associated virus (AAV) vectors. We injected a cocktail of AAV vectors 
which encode gRNAs targeting the HSV-1 immediate early genes ICP0 and 
ICP27. We measured the expression of the gRNAs in the lip and TG over the 
course of 3 days. We determined that both the ICP0 and ICP27 gRNAs had the 
highest level of expression 24 hours after injection in the lip and TG. We tested 
two different doses of AAV injections and found differential expression patterns in 
the lip and TG. The high dose AAV injection had the highest expression in the lip 
and the low dose AAV injection had the highest expression in the TG. Expression 
of gRNAs from both gRNAs at both doses declined at time points after 24 hours. 
It is possible that the difference of expression of gRNAs from the different doses 
is related to negative effects of injecting such high amounts of AAV particles. 
Additionally it will be important to determine what cells specifically are expressing 
the gRNAs in tissue. In order for the CRISPR/Cas9 endonuclease to be able to 
act on latent HSV-1 genomes, it must be delivered to neurons which are 
harboring the latent virus. Combining injection of an AAV expressing eGFP with 
immunohistochemistry, we can detect GFP expression in a specific cell types in 
tissue. Another consideration that must be addressed is multiplexing different 
gRNA targets into a single AAV particle to ensure that a single transduced cell is 
expressing multiple gRNAs.  
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5.5. Implications for research in HSV-1 animal models 
The studies presented in this dissertation provide much needed 
information about the lip scarification model of HSV-1 infection. Inoculation 
through the lip models is a physiologically relevant site for new HSV-1 
infections in humans. We sought to establish the parameters of acute and 
latent infection in order to use this model for studying HSV-1 disease in the 
orofacial epithelial tissue. We found that inoculation through the lip closely 
resembles clinical and histopathological observations previously observed in 
human infections. We demonstrated that the kinetics of virus replication in the 
lip and TG were (Hoshino et al., 2007) similar to those observed in other 
animal models (Fig. 5.1) These results suggested that the lip scarification 
model was an appropriate system for studying acute HSV-1 infections and 
models human infections in a relevant tissue site.  
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Figure 5.1. Model of acute infection following lip inoculation. Following 
scarification of the lower lip, stock HSV-1 was administered to the scratched 
site. The virus was adsorbed and initiates productive infection in the 
periphery. During replication in the lip, the virus infected innervating sensory 
neurons and gained access to the trigeminal ganglia. During the initial 
infection, viral antigen was delivered to the sub-mandibular draining lymph 
node and the anti-viral immune response was initiated. CD45+ leukocytes 
infiltrate the lower lip and trigeminal ganglia. Following immune cell infiltration, 
infection in the lip and trigeminal ganglia resolved. Infected neurons harbor 
HSV-1 genomes after the resolution of replicating virus. CD45+ cells surround 
neurons and are retained after resolution of replicating virus. 
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Figure 5.1.  
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Figure 5.2. Model of latent infection following lip inoculation. After 
resolution of primary infection, the virus establishes a latent infection in the 
trigeminal ganglia (TG). HSV-1 DNA and LAT transcripts can be recovered 
from the TG of infected mice. Tissue from both the lip and TG was capable of 
reactivating from latency when cultured after sacrifice.   Neurons in the TG 
are surrounded by CD4+and CD8+ T-cells. In the lip, CD4+ and CD8+ T-cells 
can be located in the dermis and hair follicles.  These T-cells are likely 
responding to low level viral antigen being produced from latently infected 
cells.
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We further determined if the lip scarification model could reproduce 
latency and reactivation (Fig 5.2.). We found that at time periods in which the 
virus should be considered latent based on studies performed by other 
investigators, there indeed was no replicating virus present in the lip or TG. 
The TG harbored latent HSV-1 genomes and when cultured were capable of 
reactivating from latency. The virus recovered from cultured samples was 
positive for HSV-1 antigen and produced plaques morphologically similar to 
the input stock HSV-1 McKrae strain.  
Surprisingly, we found that virus could be recovered when the lips from 
infected animals were similarly co-cultured. This novel observation suggests 
that lip scarification could be an appropriate model for studying peripheral 
latency. Peripheral latency has been suggested from clinical observations in 
corneal transplant patients (Higaki et al., 2015; Kaye et al., 1991). It has been 
reproduced with varying levels of success in mouse and rabbit models (Cook 
and Brown, 1986; Higaki et al., 2015) . There are interesting clinical 
implications to peripheral latency in the lip. Is it possible that cases of human 
reactivation can be initiated in both the TG and in the lip? It could also be that 
infectious reactivated virus is being retained in the nerve endings from 
neurons in the TG, awaiting only an appropriate trigger to be released into the 
peripheral environment. Further experiments are needed to confirm the 
presence of latent HSV-1 genomes being harbored in the lip. Additionally, the 
molecular basis of latent genomes in the lip needs further exploration. 
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Peripheral latency could exist in a form different from what is seen in the TG, 
thus eluding detection.  
Finally we explored delivery of CRISPR/Cas9 gRNAs into relevant tissues 
by AAV vectors. We found that after local delivery of AAV vectors into the 
lower lip, we could detect gRNA expression in both the lip and TG. The 
highest level of expression of the gRNAs was 24 hours after injection. These 
results confirm that timing of AAV vector injection is going to be critical for 
studying CRISPR/Cas9 gene editing of the HSV-1 genome. We can also 
exploit this timing to determine the effect of CRISPR/Cas9 in different tissue 
sites.  
It would be quite interesting if CRISPR/Cas9 were capable of reducing 
virus replication during acute infection. A reduction in viral load in the lip could 
mean a reduced viral load in the TG. A reduced viral load entering the TG 
would reduce the number of infected neurons and reduce the capability and 
frequency of reactivation (Hoshino et al., 2007). However, CRISPR/Cas9 
treatment is not likely to be implemented during primary acute infection. Most 
people are unaware of when they are first exposed until symptoms of primary 
infection occur. By that time, the virus has already infected the innervating 
sensory neurons and gained access to the TG.  
The most promising course of treatment for HSV-1 infections using 
CRISPR/Cas9 would be to target the latent HSV-1 genome maintained in 
neurons. If the CRISPR/Cas9 and gRNAs could be effectively delivered and 
expressed in the neurons, the latent HSV-1 genome could be edited. 
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Recurrent infections could be eliminated by targeting HSV-1 genes necessary 
for reactivation. It is also conceivable that the genome could be targeted in a 
way to cause large portions of the genome to be deleted. Similar approaches 
are being used to target integrated human immunodeficiency virus type 1 
(HIV-1) in infected T cells. The integrated virus has identical copies of the 
long terminal repeat (LTR) flanking the viral genome in T cells (Kaminski et 
al., 2016). By targeting the LTR sequence on both sides of the viral genome, 
double-stranded break repair mechanisms will remove the integrated viral 
genome. The latent HSV-1 genome must be examined for similar sites with 
appropriate protospacer sequences that will make those sites accessible to 
Cas9 mediated cutting.  
The value of examining CRISPR/Cas9 treatment during acute infections 
lies in optimizing the design and delivery of Cas9 and gRNAs. To only look for 
efficacy in CRISPR/Cas9 treatment in mice which already have established a 
latent infection would be prohibitive in both time and money. The design of 
gRNAs and the vehicle used for delivery can be evaluated in vivo during the 
acute infection. We can analyze infected tissue samples for evidence of 
genome editing occurring in the HSV-1 genes targeted by the gRNAs. This 
information would confirm that the Cas9 and gRNAs are delivered and 
expressed at usable levels. 
The in vivo acute infection information will inform the eventual experiments 
focusing on editing the latent HSV-1 genome. Mice which are latently infected 
can be injected with the CRISPR/Cas9 treatment through either the lip or 
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systemically through the intraperitoneal or intravenous routes. The genomic 
editing of the latent HSV-1 genome can be assessed with the surveyor assay 
from infected tissue. The most important experiment will be to compare 
reactivation frequencies from mice which received CRISPR treatment 
compared to those receiving empty vehicle. A significant reduction in 
reactivation from treated mice would suggest that CRISPR therapy holds 
promise for treating latent HSV-1 infections in humans.  
In conclusion, we characterized the acute events of HSV-1 infection 
following inoculation of the lower lip in mice. We found that mice were 
productively infected and had pathology consistent with human infections. 
The virus gained access to the TG and established a latent infection. The 
virus was capable of reactivating from latency to produce new infectious 
virions in culture. The development and characterization of a biologically 
relevant mouse model of HSV-1 infection in the lip is a crucial first step to the 
development of novel therapeutics and interventions, such as the CRISPR-
mediated removal of HSV-1 genomes attempted in Chapter IV. 
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